

## **ERA-NET: Aligning national/regional translational cancer research programmes and activities**

### **TRANSCAN-2**

**Joint Transnational Call for Proposals 2016 (JTC 2016):**

**“Minimally and non-invasive methods for early detection and/or progression of cancer”**

---

## **Call Text**

---

**Submission deadline for pre-proposals:**

**13<sup>th</sup> February 2017 at 16:00 (CET)**

**Electronic proposal submission system: [https://secure.pt-dlr.de/ptoutline/app/transcan\\_2016](https://secure.pt-dlr.de/ptoutline/app/transcan_2016)  
(Online submission will be possible from 2<sup>nd</sup> January 2017)**

For further information, please visit  
[www.transcanfp7.eu](http://www.transcanfp7.eu) or  
Contact the **Joint Call Secretariat (JCS)** at:

**The Dutch Cancer Society (KWF kankerbestrijding)**

**E-mail: [transcan\\_jtc2016@kwf.nl](mailto:transcan_jtc2016@kwf.nl)**

**Bart Hattink**

**Phone: +31 20 5700468**

## Content

|   |    |
|---|----|
| MOTIVATION .....  | 3  |
| 2. AIM OF THE CALL .....  | 5  |
| 2.1 Scientific project .....  | 5  |
| 2.2 Capacity building activities .....  | 7  |
| 3. CALL IMPLEMENTATION BOARDS .....   | 8  |
| 4. APPLICATION .....  | 8  |
| 4.1 Eligibility criteria .....  | 8  |
| 4.2 Submission of joint proposals .....   | 10 |
| 5. EVALUATION .....   | 11 |
| 5.1 Evaluation criteria .....   | 11 |
| 5.2 Scoring .....   | 12 |
| 5.2.1 Range and interpretation of the scores .....  | 12 |
| 5.2.2 Thresholds and weighting .....  | 13 |
| 5.3 Eligibility check of pre-proposals and first step of evaluation .....   | 13 |
| 5.3.1 Eligibility check .....   | 13 |
| 5.3.2 Evaluation of pre-proposals .....   | 13 |
| 5.4 Eligibility check of full proposals and second step of evaluation .....   | 14 |
| 5.5 Funding decision .....  | 15 |
| 6. FINANCIAL AND LEGAL ISSUES.....  | 15 |
| 6.1. Funding model and funding details .....  | 15 |
| 6.2 Research Consortium Agreement, ownership of intellectual property rights,<br>ethical issues.....                        | 16 |
| 6.3 Confidentiality of proposals.....   | 17 |
| 7. REPORTING AND DISSEMINATION .....  | 17 |
| 8. CONTACT AND FURTHER INFORMATION.....   | 17 |
| <br>  |    |
| ANNEX 1. CONTACT INFORMATION OF THE NATIONAL/REGIONAL FUNDING<br>ORGANISATIONS PARTICIPATING IN TRANSCAN-2 JTC 2016.....    | 19 |
| ANNEX 2. INDICATIVE FUNDING COMMITMENT OF THE FUNDING<br>ORGANISATIONS PARTICIPATING IN TRANSCAN-2 JTC 2016.....            | 24 |
| ANNEX 3. ELIGIBILITY OF BENEFICIARY INSTITUTIONS FOR THE FUNDING<br>ORGANISATIONS PARTICIPATING IN TRANSCAN-2 JTC 2016..... | 26 |
| ANNEX 4. NATIONAL/REGIONAL REGULATIONS AND CONTACT INFORMATION .  | 29 |

## MOTIVATION

Screening of the general population, risk stratification, surveillance of high risk groups, and diagnosis represent different steps of a multimodal approach of early cancer detection, that greatly increase the chances for successful treatment as generally prognosis worsens with advancing stage. Minimally invasive methods, such as the identification of specific biomarkers in body fluids or innovative imaging approaches at early stages of cancer may help to detect the disease before any clinical manifestation, with a better chance to provide therapies with a curative intent. However, there is a certain risk of over-diagnosis and over-treatment.

Cancer screening programmes implemented so far have been designed to test people from the general population with an average risk to develop the disease, mostly in a specific age group. The discovery of highly penetrant gene mutations (e.g. *BRCA1* and *BRCA2* for breast cancer, *HNPCC* genes for colon cancer) already paved the way for identifying people with high hereditary risk of cancer. Recent advances in sequencing of the human genome are likely to identify additional risk indicators. For individuals known to be at elevated risk for certain tumour diseases, general cancer screening programmes are not appropriate or start too late in life. Increased knowledge of promising biomarkers, such as serum, urine, faecal or blood-based (genetic, or immunochemical) markers of cancer development, will likely provide efficient tools for risk stratification for targeted screening, i.e. people differing by risk level for developing certain cancer types based on a combination of biomarkers and other risk factors. The benefits of any cancer screening programme will be offset by possible harms, such as false-positives, over-diagnosis, and over-treatment. A screening programme becomes feasible if it does more good than harm at reasonable costs.

The impact of early detection on patient-important outcomes is generally remarkable when dealing with relatively homogeneous, slow-growing tumours, whose precursors can be appropriately identified and removed, e.g. pre-cancerous lesions for cervical and colorectal cancer. However, cancer is a biologically heterogeneous disease, whose behaviour may range from indolent to highly aggressive. Current efforts are increasingly focused on deciphering such complexity and its consequences in terms of disease onset and patterns of disease progression. Within such a context, the broad group of science and engineering disciplines known as ‘omics’, along with imaging techniques, may further add to current knowledge on cancer heterogeneity. Strategies for risk stratification and identification of patients with poor prognosis may result in the administration of more targeted therapies, improved treatment outcomes and more appropriate outcome interpretation. At the same

time, the identification of patients with good prognosis may reduce over-treatment, including potential side-effects of treatment, and thus decrease unnecessary burden to patients and healthcare costs.

Despite major achievements in the understanding of the molecular roots of cancer, validation at the general population level of minimally invasive methods for early detection and prediction of cancer progression remains a poorly explored area. Thus far the interest of the pharmaceutical industry has been strongly focused on areas requiring immediate and effective solutions, i.e., the metastatic setting. These latter efforts are currently paralleled by actions leading to implementation of early detection strategies in groups of people with high risk of cancer and adaptation of treatment strategies according to the risk of progression for patients diagnosed at an early stage of cancer. These actions are particularly attractive at an academic institution level in light of their potential impact on cancer incidence and mortality.

The national/regional funding organisations listed below have agreed to participate in the TRANSCAN-2 Joint Transnational Call for proposals 2016 (JTC 2016):

- Research Foundation - Flanders (FWO), Belgium
- Fund for Scientific Research (FNRS), Belgium, French speaking community
- Estonian Research Council (ETAg), Estonia
- National Cancer Institute (INCa), France
- ARC French Foundation for Cancer Research (ARC Foundation), France
- Federal Ministry of Education and Research (BMBF), Germany
- General Secretariat for Research & Technology (GSRT), Greece
- The Chief Scientist Office of the Ministry of Health (CSO-MOH), Israel
- Ministry of Health (MoH), Italy
- Alliance Against Cancer (ACC), Italy
- Lombardy Foundation for Biomedical Research (FRRB), Italy
- State Education Development Agency (VIAA), Latvia
- Dutch Cancer Society (DCS), Netherlands
- Research Council of Norway (RCN), Norway
- Norwegian Cancer Society (NCS), Norway
- National Centre for Research and Development (NCBR), Poland
- Slovak Academy of Sciences (SAS), Slovakia
- Ministry of Education Science and Sport (MIZS), Slovenia
- Spanish Association Against Cancer Scientific Foundation (AECC FC), Spain
- National Institute of Health Carlos III (ISCIII), Spain

- The Foundation for the support of the Applied Scientific Research and Technology in Asturias (FICYT), Spain
- Ministry of Science and Technology (MoST), Taiwan
- Scientific and Technological Research Council (TUBITAK), Turkey

## 2. AIM OF THE CALL

### 2.1 Scientific project

Translational research proposals of the TRANSCAN-2 JTC 2016 call must focus on:

**“Minimally and non-invasive methods for early detection and/or progression of cancer”**

Minimally invasive methods refer to techniques that have limited physical damage, burden and pain associated with the detection method, resulting in less anticipated stress, a higher screening/clinical care uptake, and more efficient and cost-effective screening and care. The studied methods should be sensitive for early detection of cancer, its staging and prediction of progression. Examples are: individual or combination of molecular, immunochemical, proteomic or genetic markers in body fluids and blood or cell samples, as well as macroscopic, microscopic and molecular imaging techniques (e.g. improved ultrasound technology, molecular imaging with contrast agents, fluorescence imaging, radiolabelling). This call excludes invasive methods, such as image-guided biopsy or surgery.

In the context of translational cancer research, this topic will comprise three specific aims. Proposals will have to cover at least one of the specific areas listed under each undermentioned aim.

**Aim 1: Risk stratification to distinguish groups by susceptibility for development or progression of cancer based on molecular biomarkers and established cancer risk factors, such as age, medical history, anthropometrics (e.g., body mass index, waist circumference), and lifestyle related determinants (e.g., diet, physical exercise, environmental exposure and medication).**

- Risk stratification for cancer development (susceptibility to develop cancer) using minimally invasive methods (imaging, biomarkers assessment in body fluids) to identify high risk groups of individuals who will benefit most from a more intensive and/or invasive screening.
- Risk stratification for cancer progression (biomarker(s) or clinical characteristic(s) with a prognostic value, i.e. that provides information on the likely outcome of the cancer in (untreated) individuals). Detection of tumour promoting subpopulations, those with enhanced ability to drive tumour progression.

**Aim 2: Validation of multiparametric methods, using the combination of promising<sup>1</sup> biomarkers (genomic, proteomic, metabolomic and imaging markers) to improve our capability for early detection or progression of cancer**

Different tumour markers show different sensitivity towards different types of tumours. Combining multiple markers significantly increases the ratios of positive cancer diagnosis. Even though the increase in sensitivity when combining markers and tools might be accompanied by a decrease in specificity, tumour markers combinations may still play an important role in early tumour detection as well as in prediction of cancer progression. As high throughput genomic assays become more accessible, working with largescale data sets requires user-friendly and powerful tools and techniques to help researchers manage, analyse and integrate big data from genomics. The development and implementation of adequate bioinformatics techniques are of essential importance. Biomarkers that are suitable for automated measurement are promising tools.

- Molecular tumour markers: increase sensitivity of detecting genetic, epigenetic or proteomic markers, including circulating tumour cells (CTC techniques), exosomes, tumour DNA, circulating free DNA in plasma and other fluids, micro RNA and integration with metabolomic assays.
- Imaging markers: such as low radiation CT scans or intravenously delivered fluorescent peptide probes.
- Bioinformatics techniques: techniques for mining complex genomic/biomarkers data.

**Aim 3: Improve clinical evidence of the minimally invasive methods**

Important criteria to evaluate a biomarker are described in the [ACCE model](#). It is important to acknowledge these criteria when describing the outcome measures and future directions of the project plan.

- Analytical validity, clinical validity, and clinical utility: Evaluation (or describe the planning) of the impact of minimally invasive methods on patient outcome (less invasive detection, increased life expectancy, or reduced morbidity) and properties such as sensitivity and specificity. Ethical, legal, and social implications (could also be considered): Evaluation of implication and implementation aspects, e.g. acceptance of personalised screening based on risk stratification.

Projects should be built from solid and established research and should be relevant with regard to possible improvements in clinical practices. Projects should describe how the

---

<sup>1</sup> Biomarkers that already have shown to have predictive value, but need to be validated in an independent heterogeneous target population

research results would fit in current screening programmes and/or (inter)national clinical cancer detection and diagnostic guidelines and how they can be implemented in the future.

Proposals reach high impact if they meet the following requirements:

- a) There is a clear added value of the transnational collaboration.
- b) They are presented by a sustainable network/consortium. As TRANSCAN-2 can only support the consortium until the end of the project, it is stimulated to describe a plan for future collaboration and to guarantee the sustainability of the consortium with regard to the next translational steps and long term data accessibility for all partners.
- c) They are focussed on cancers without established screening programmes. Screening programmes for rare or very aggressive tumour types or subtypes, may have high impact as these are often discovered in a late stage, which is associated with a high mortality rate.

The following types of research projects are excluded from the call:

1. Analysis of preclinical models (cell lines and animal models) only.
2. Phase III and IV clinical trials.
3. Studies not compliant with the COMMISSION REGULATION (EC) No 800/2008 ([link](#)), with specific reference to the articles 30, 31, 32, and 33. For full reference, please see also the COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS of 20.12.2011 ([link](#)). Studies not compliant with the Commission Regulation (EU) No 651/2014 of 17 June 2014 ([link](#)).

## 2.2 Capacity building activities

Translational research has the ambition to remove barriers to multidisciplinary collaboration.

It is envisioned that clinicians, researchers and the operational staff from various sectors (academia, industry, regulatory bodies) will effectively work together to expedite the translation of scientific discoveries to clinical application and to more rapidly fuel research directions with observational or clinical findings. In fact, the complexity of the process requires, at the individual and collective levels, the creation of translational medicine research interfaces/infrastructures. To reach that goal, TRANSCAN-2 supports capacity building activities for promoting the formation and upgrading of multidisciplinary teams in an integrated process: i) exchange/mobility of individual researchers/professionals within the consortium in order to bring new expertise to an existing multidisciplinary translational team, and/or ii) recruitment of individual researchers/professionals by a translational research team in order to cover expertise and “knowhow” unavailable in the existing team. This type of

activities, when present, will be supported within the projects which will be selected for funding under TRANSCAN-2 JTC 2016.

Thus, applicants may add an additional part to cover these activities (with an associated separate budget, in compliance with the rules of the respective national/regional funding organisations). These capacity building activities have to be fully coherent with the objectives of the research project, and aimed to strengthening the ability of participating team(s) to perform the work detailed in the project plan as well as to improve, in the long term, the quality and potential of the translational research performed by the team(s). Depending on the project these activities could be (the following examples are indicative only, and neither exhaustive nor prescriptive): 1) exchanges/mobility of investigators (especially young investigators) between teams and countries participating in the project, 2) short term training of scientists, operational staff, etc., 3) training technical workshop dedicated to relevant aspects of the scientific work planned in the project, 4) short training (1 or few weeks) of several partner teams by one expert, etc. Activities related to the dissemination of results such as hosting a symposium, conferences etc. are out of the scope of this capacity building activities component.

### **3. CALL IMPLEMENTATION BOARDS**

The Call Steering Committee (CSC) and the Scientific Evaluation Committee (SEC) will manage the evaluation procedure of pre-proposals and full proposals and the final selection of research projects, with the support of the Joint Call Secretariat (JCS).

The CSC is composed of one single representative from each national/regional funding organisation participating in TRANSCAN-2 JTC 2016. The CSC will supervise the preparation and the implementation of the call and will take all decisions concerning the call. Based on the ranking list established by the SEC, the CSC will take the final decision on the proposals to be funded. Members of the CSC are not allowed to submit proposals to this call.

The SEC is a panel of internationally recognised scientific experts in charge of the evaluation of submitted pre- and full proposals. SEC members are not allowed to submit or participate in proposals within this call. SEC members must sign declarations on conflicts of interest and confidentiality. In the second step of evaluation (full proposals stage), in addition to the SEC members, external peer reviewers chosen for their knowledge in specific fields covered by the proposals will also contribute to the evaluation.

## **4. APPLICATION**

### **4.1 Eligibility criteria**



Joint transnational research proposals may be submitted by applicants belonging to one of the following categories depending on national/regional eligibility rules as specified in Annex 3:

- Academic research groups (from universities or other higher education or research institutions).
- Clinical/public health sector research groups (from hospitals/public health and/or other health care settings and health organisations).
- Enterprise's research groups (depending on national/regional eligibility rules), with particular emphasis on small and medium-sized enterprises.

**Please note that the inclusion of a non-eligible partner in a proposal will lead to the rejection of the entire proposal without further review.** With the exception, in the phase between the pre- and full proposal a consortium gets the opportunity to exchange or delete a partner if the representative national/regional organisation (and not the other funding organisations) considers the partner as non-eligible.

Only transnational projects will be funded. Each research consortium asking for funding must involve a minimum of three (3) eligible research groups and a maximum of seven (7) research groups. The maximum number of 7 research groups could be increased only with partners from the following countries : Estonia, Latvia and Slovakia, up to a maximum of 3 additional partners from the 3 countries, to reach a maximum total of 10 research groups in a proposal. In each consortium, groups applying for funding must be from at least three (3) different countries participating in the call. In addition, a consortium must not involve more than two (2) research groups from one country (in such cases the minimum number of groups must be 4, coming from 3 different countries).

In order to strengthen the European translational cancer research area, a wide inclusion of research teams from all the countries/regions participating in the call is encouraged, with a particular attention to research teams from Estonia, Latvia, and Slovakia. A consortium may include one (1) research group (included in the maximum number of seven (7)) with own funding from a country/region not partner in this call, at the stage of the pre-proposal submission, this group must provide a written confirmation that its funding is already secured.

Each consortium must nominate a coordinator. The coordinator will be responsible for the scientific management (such as controlling, reporting, intellectual property rights issues, etc.) and will act as the interface with the JCS and the CSC. Each research team will be

represented by one principal investigator only, who will be the contact person for the respective national/regional funding organisation.

Each consortium must involve at least one basic or pre-clinical research team and one clinical team. It is also recommended to include expert teams in methodology, biostatistics or bioinformatics, depending on the type of work planned. Consortia may also involve other teams with specialised skills and know-how (biobanks, model systems, technological platforms, etc.) or expertise (epidemiology and molecular epidemiology, early phase clinical trials, public health, ELSI, etc.). Consortia should have sufficient critical mass to achieve ambitious scientific, technological and medical goals and, along with the particular contribution of each research team, should clearly demonstrate its transnational added value. The translational nature of the research results is the key goal of TRANSCAN-2 and, therefore, each consortium should also clearly demonstrate a knowledge transfer towards clinical, public health and/or industrial applications.

While applications will be submitted by the coordinator, the individual research groups will be funded by the funding organisation from their country/region that is participating in the TRANSCAN-2 JTC 2016. The applications are therefore subject to eligibility criteria of national/regional funding organisations. In case of ineligibility of one of the teams, the eligibility of the consortium as a whole would be at stake. Applicants should refer to the annexes containing all the specific national/regional eligibility criteria (see Annex 4, national/regional regulations and contact information) and should contact their respective national/regional funding organisation contact points for additional clarification (see Annex 1. Contact information of the national/regional funding organisations).

Please note that an eligibility check before the pre-proposal submission is mandatory for the Ministry of Health (MoH), Italy.

The duration of the projects shall not exceed three (3) years. According to the eligibility criteria of the funding organisations contributing to the TRANSCAN-2 JTC 2016, a research group may however receive funding for less than three years.

#### 4.2 Submission of joint proposals

TRANSCAN-2 JTC 2016 will be implemented through a two-stage submission procedure: pre-proposals and full proposals. Both pre- and full proposals must be written in English and must be submitted to the JCS by the coordinator through the electronic submission system exclusively.

In preparing the proposals, applicants should strictly follow the rules described in this call text and in the document entitled “Guidelines for applicants”, and use the application forms

available from the electronic submission system ([https://secure.pt-dlr.de/ptoutline/app/transcan\\_2016](https://secure.pt-dlr.de/ptoutline/app/transcan_2016)) or from the TRANSCAN website ([www.transcanfp7.eu](http://www.transcanfp7.eu)). Applicants should take note of individual national/regional rules, and contact their national/regional contact points for specific questions.

The pre-proposals must be submitted to the electronic submission system no later than the 13<sup>th</sup> of February 2017, at 16:00 (Central European Time, CET). The information relating to the selected pre-proposal will be communicated to the coordinators by April 2017.

The information provided in the pre-proposal application is binding for the entire application process. Thus, any substantial changes between the pre-proposal and the full proposal (e.g. composition of the consortia, objectives of the project, etc.) must be communicated in advance to the JCS with detailed justification and will only be allowed by the CSC under exceptional circumstances.

The full proposals will have to be submitted to the electronic submission system not later than the 7<sup>th</sup> of June 2017 at 16:00 (Central European Summer Time, CEST). Please note that full proposals will only be accepted from applicants explicitly invited by the JCS to submit them.

The decision on the results of the full proposals evaluation meeting will be communicated to all the (successful and unsuccessful) coordinators in October 2017. The coordinators of the full proposals will receive a summary of the evaluation conclusions in due time.

## 5. EVALUATION

### 5.1 Evaluation criteria

Pre-proposals and full proposals will be assessed according to following criteria.

#### 1. Excellence

- a. Scientific quality of the proposal: soundness of the rationale including transdisciplinary considerations, clarity of the objectives, expected progress beyond the state-of-the-art, international competitiveness.
- b. Relevance of the project regarding the topic (minimally and non-invasive methods for early detection and/or progression of cancer) and the overall objective (translational cancer research) of the call; availability and quality of preliminary data.

#### 2. Impact

- a. Potential impact with reference to the development, dissemination and use of project results: potential impact of the expected results on cancer control, in terms of translation into public health or clinical practices (enhancing innovation capacity and integration of new knowledge) and/or into pharmaceutical/industrial applications; appropriateness of measures for the dissemination and/or exploitation of project results including socio-economic aspects and anticipation of intellectual property issues (patenting, industrial

exploitation, marketing, etc.).

- b. Impact with reference to strengthening the translational capacity building activities:  
This sub-criterion will be assessed at the level of the full proposal only and solely for the scientific proposals recommended for funding.

The assessment of the capacity building component and associated budget will be performed under this sub-criterion after the scientific assessment of the proposal: hence, a proposal could be recommended for funding without the part related to capacity building activities if this part is evaluated as “poor”.

The assessment under this sub-criterion will be performed independently using the following:

- Content: relevance and coherence of the capacity building activities with the proposal objectives.
- Candidate: background (scientific, medical, etc.), coherence with the CV, scientific production.
- Host team: expertise of the host team in the field, research qualification of the responsible person.

### **3. Quality and efficiency of the implementation**

- a. Coherence and effectiveness of the work plan: appropriateness and feasibility of the methodology (including the clinical trial if applicable) and associated technologies used, with particular regard to the study design, the study population(s), study endpoints.
- b. Statistical/bio-statistical aspects and power calculation (including the clinical trial if applicable): study design; sampling calculations; appropriateness and robustness of statistical analyses: adequateness of endpoints.
- c. Quality of the transnational research consortium: experience of the research partners in the field(s) of the proposal (for young teams: appropriateness of their current work and training of their members); quality of the collaboration between the research teams and added value of the research consortium as a whole.
- d. Appropriateness of the management structures and procedures, including risk and innovation management.
- d. Appropriateness of the allocation of tasks and resources to be committed (personnel, equipment, etc.) and of the estimated budget.
- e. Compliance with ethical rules and regulatory aspects, please refer to paragraph 6.2 of this document for requirements and advise.

## **5.2 Scoring**

### **5.2.1 Range and interpretation of the scores**

A scoring system from 0 to 5 will be used to evaluate the proposals performance with respect to each evaluation criterion, as follows:

- 0: fails to address the criterion or missing information;
- 1: criterion poorly addressed/serious weaknesses;
- 2: fair/ some weaknesses;
- 3: good/ shortcomings are present;
- 4: very good/ criterion well addressed;
- 5: excellent.

Please note that half marks may be given

### 5.2.2 Thresholds and weighting

The threshold for individual criteria is 3. The overall threshold, applying to the sum of the individual scores, is 10.

To determine the ranking:

- the score of the criterion “impact” will be given a weight of 1.5.  
In case of equal score, the “impact” score will be considered first, then the score of “excellence” and then of “quality and efficiency of the implementation”.

## 5.3 Eligibility check of pre-proposals and first step of evaluation

### 5.3.1 Eligibility check

The JCS will examine all pre-proposals to ensure that they meet the call’s formal criteria (date of submission, number of participating partners, and countries/regions of provenience, inclusion of all necessary information in English, adherence to the application forms, document length). The JCS will forward the pre-proposals to the national/regional funding organizations, which will perform a formal check of compliance with their respective regulations.

After completion of the eligibility check, the CSC will take the final decision; the pre-proposals not considered eligible will be rejected without further review. The coordinators of the non-eligible pre-proposals will be informed accordingly by the JCS.

### 5.3.2 Evaluation of pre-proposals

Pre-proposals passing the formal eligibility checks will be reviewed by the SEC panel.

All necessary steps will be taken by the JCS and the CSC to ensure that the SEC members have no conflict of interest for those proposals that they are asked to review. The SEC members will be required to formally declare that no conflict of interest exists at any time of their evaluation duty and will sign a confidentiality agreement concerning all documents and the entire process.

Each pre-proposal will be allocated to at least two (2) SEC members (one of whom will act as rapporteur). The SEC will meet, discuss the pre-proposals and establish a ranking list in accordance with the pre-proposals respective merit. Then, the CSC will decide, based on the SEC recommendations and budget consideration, how many pre-proposals will be invited to submit a full proposal. The JCS will communicate to each project coordinator the final decision with respect to their own application. Successful applicants will be invited by the JCS to submit a full proposal, with possible recommendations on the project from the SEC and the JCS.

#### 5.4 Eligibility check of full proposals and second step of evaluation

An eligibility check of the full proposals will be performed by the JCS to ensure that they meet the formal criteria of the call and have not changed substantially from the respective pre-proposals. A full proposal may be excluded from further review, if criteria are not met or if the proposal objectives or the composition of the consortium deviate substantially from the previously submitted pre-proposal. In any case, major changes must be communicated in advance to the JCS, which will contact the concerned national/regional funding organizations to discuss the issue; a formal decision on whether such an exceptional change may be justified will be taken by the CSC. Each full proposal will be allocated to two (2) SEC members, possibly those who had reviewed the corresponding pre-proposal, an additional methodology review by one (1) SEC methodologist member, and to at least two (2) external reviewers. One of the SEC members will be appointed as rapporteur. The SEC members and the external reviewers will independently assess the full proposals according to the evaluation criteria mentioned above, and will deliver their evaluation reports to the JCS (via an electronic evaluation system).

##### 5.4.1 Rebuttal stage

Once the evaluation by both the SEC members and the external reviewers is completed, each proposal coordinator will have access, through the electronic submission system, to the anonymous evaluation reports (not to the assigned scores) by the SEC members and the external reviewers. At this stage, each coordinator will have the opportunity to comment the evaluations, to reply to reviewer's questions and to clarify factual errors or misunderstandings. However, issues which are not related with reviewers' comments or questions cannot be addressed and the work plan cannot be modified. The resubmission of the full proposal is not permitted in any case.

This response to reviewers' comments is optional and must be submitted exclusively by the coordinator of the proposal through the electronic submission system, which will be available from the **15<sup>th</sup> of August 2017 to the 24<sup>th</sup> of August 2017 at 16:00 (Central European Summer Time, CEST)**.

In preparation of the second SEC meeting, all SEC members will get access to the evaluation reports and to the optional responses submitted by the coordinators following the rebuttal stage. During the second SEC meeting, each full proposal will be presented by the rapporteur and discussed by the SEC members on the basis of the individual evaluation reports to reach consensus scoring. As a result of these discussions and as an outcome of the SEC meeting, a ranking list of the full proposals will be established.

### 5.5 Funding decision

After the end of the evaluation process, on the basis on the ranking list established by the SEC and on the resources available for committed funds, the CSC will establish a final list of the projects to be funded. The CSC recommendations will be sent to the national/regional funding organisations for their final decisions.

The JCS will communicate to all project coordinators the final decision along with a summary of the evaluation conclusions.

## 6. FINANCIAL AND LEGAL ISSUES

### 6.1. Funding model and funding details

The TRANSCAN-2 JTC 2016 funding organisations have agreed to launch a joint call using the “virtual common pot” funding model. This means that funding will be made available by each national/regional funding organisation according to their specific regulations, for research groups in their country/region.

The funding rate within the call will be variable up to a maximum of 100% of the funds requested, according to national/regional rules. Funding is granted for a maximum of three years according to national regulations. Each research project partner (including the project coordinator) will get a separate funding contract/letter of grant according to national/regional regulations from his/her national/regional funding institutions.

As a general rule, no changes to the composition of research consortia or in budget may occur during the contract/letter of grant. Any minor changes will have to be well justified and the relevant funding organizations will decide upon the proper action to be taken. However, in case of major changes, an independent expert may be consulted to help with the final decision of the funding organizations. The research partners shall inform the coordinator, the JCS and her/his national contact person of any event that might affect the implementation of the project.

Depending on the time needed for the administration of granting funds to the respective national/regional research groups, individual tasks of a research consortium are expected to start by April 2018. The official start date shall be communicated in the annual reports and shall appear in the consortium agreement established in accordance to section 6.2 below.

**Prior to submitting a proposal, applicants should take note of individual national/regional rules described in the Annex 4 of this document in order to verify their eligibility, the eligible costs and potential budget available. Applicants are strongly encouraged to contact their national/regional funding organisations (see Annex 1. Contact information of the national/regional funding organisations) for any clarification.**

## 6.2 Research Consortium Agreement, ownership of intellectual property rights, ethical issues

It is mandatory for a funded research project consortium to sign a Consortium Agreement (CA), addressing the issues indicated in the document "Guidelines for Applicants". See [link](#) for an EU example of a CA. For the composition of the CA, the research consortium is strongly recommended to see legal assistance of a TTO (Technology Transfer Office) at their own institute. Also, the research consortium is strongly recommended to sign this CA before the official project start date. In any case the CA has to be signed no later than six months after the official project start date. The signed consortium agreement must be made available to the concerned TRANSCAN-2 JTC 2016 funding organizations.

Results and foreground IPR resulting from projects funded through the TRANSCAN-2 JTC 2016 will be owned by the organization that employs the participant who creates the results, respecting to international/national/regional rules on IPR. If several participants have jointly carried out work generating new IPR, they shall agree amongst themselves in the CA as to the allocation of ownership of IPR, taking into account their contributions to the creation of those IPR. [European Commission's guidelines](#) on IPR issues should be respected in TRANSCAN-2 JTC 2016 research projects.

The owner may protect foreground IPR at its own cost and risk, and grants the other parties in the research consortium free user rights of both background and foreground IPR as far as necessary for executing the TRANSCAN-2 JTC 2016 research project. Licencing or transfer of foreground IPR between consortium partners or to third parties will be on the basis of a market-based compensation. The consortium partners grant each other a free user right of foreground IP for non-commercial research and education purposes during and after the TRANSCAN-2 JTC 2016 research project.

The results of the research project and IPR created should be disseminated and made available for use, whether for commercial purposes or not, in order to maximize public benefit. Dissemination should not conflict protection of IPR. In the CA the parties agree on the procedures for delaying dissemination of results to enable protection of IPR. The delay may not exceed 120 days after the originally planned date of dissemination.



The TRANSCAN-2 JTC 2016 funding organizations shall have the right to use reports, documents, and information submitted by the research partners for their own purposes, provided that the owners' rights are respected.

Any ethical issues, arising for instance if a research project includes a study on patients, should be addressed at the proposal submission stage, and subsequent authorization presented at the latest to the national/regional funding organizations, before the process of grant negotiation.

### 6.3 Confidentiality of proposals

Proposals and any relating information shall be kept confidential by the SEC members (including SEC methodologist member), the external reviewers and the CSC members. Proposals shall not be used for any purpose other than the evaluation and subsequent monitoring of the funded projects.

Full proposals will be required to include a publishable summary, which will clearly identify the main goals of the project. If a proposal is funded, this information will be published on the TRANSCAN-2 website. All other project details shall remain strictly confidential.

## 7. REPORTING AND DISSEMINATION

The coordinator of a funded transnational research consortium must submit annual scientific project reports (within 4 months after the end of a calendar year), and a final scientific project report (within 3 months after the end of the project) to TRANSCAN-2. All reports must be written in English and comply with the reporting form templates (one for the annual reports and one for the final report) that will be provided to the coordinators of the funded projects in due time.

In addition to these centrally-administered TRANSCAN-2 reports, principal investigators may be asked to submit financial and/or scientific reports to their national/regional funding organizations. Each individual contract/letter of grant will be monitored by the respective national/regional funding organizations.

In case of serious difficulties in the conduct of the research project, the coordinator shall promptly inform the JCS and the relevant funding organizations. These funding organizations will decide upon the proper actions to be taken.

Funding recipients must ensure that all results (publications, etc.) arising from the project include a proper acknowledgement that the project is collectively supported by the national funding organisations under the framework of the ERA-NET TRANSCAN-2 initiative.

The coordinators and/or principal investigators may be invited to present the results of their projects at TRANSCAN-2 symposia.

## 8. CONTACT AND FURTHER INFORMATION

The JCS is set up at the Dutch Cancer Society, the Netherlands. The JCS will assist the CSC during the implementation of JTC 2016 as well as during the monitoring phase (until 3 months after the funded research projects have ended). The JCS will be responsible for the central management of the call evaluation and monitoring. The JCS will be the primary

contact referring to the TRANSCAN-2 JTC 2016 procedures between the research consortia, the funding organizations (CSC) and the peer reviewers (SEC members and external experts).

Further information on TRANSCAN-2, the TRANSCAN2 JTC 2016 and its planned time schedule is available at the TRANSCAN website: <http://www.transcanfp7.eu>. Before submitting a proposal, it is strongly advised to contact the national/regional funding organizations for any questions regarding JTC 2016 (see Annex 1).

## ANNEX 1. CONTACT INFORMATION OF THE NATIONAL/REGIONAL FUNDING ORGANISATIONS PARTICIPATING IN TRANSCAN-2 JTC 2016

| Country / region                   | Funding organisation                                       | Website  | National / regional contact  |
|------------------------------------|--|--|--|
| Belgium:<br>Flemish region         | Research Foundation - Flanders (FWO)                       | <a href="http://www.fwo.be">www.fwo.be</a>                       | <p><b>Dr. Olivier BOEHME</b><br/>Science Policy Advisor<br/>Research Foundation - Flanders<br/>Egmonstraat 5<br/>1000 Brussels<br/>Belgium<br/>Tel. +32 2 550 15 45<br/>E-mail: <a href="mailto:eranet@fwo.be">eranet@fwo.be</a></p> <p><b>Toon MONBALIU</b><br/>Advisor Research Affairs<br/>Research Foundation - Flanders<br/>Egmonstraat 5<br/>1000 Brussels<br/>Belgium<br/>Tel. +32 2 550 15 70<br/>E-mail: <a href="mailto:eranet@fwo.be">eranet@fwo.be</a></p> |
| Belgium:<br>French speaking region | Fund for Scientific Research (FNRS)                        | <a href="http://www.fnrs.be">www.fnrs.be</a>                     | <p><b>Dr. Arnaud GOOLAERTS</b><br/>Scientific Officer<br/>FRS-FNRS<br/>Rue d'Egmont 5 B-1000 Brussels<br/>Belgium<br/>Tel. +32 2 504 93 28<br/>E-mail: <a href="mailto:arnaud.goolaerts@frs-fnrs.be">arnaud.goolaerts@frs-fnrs.be</a></p>  |
| Estonia                            | Estonian Research Council (ETAg)                           | <a href="http://www.etag.ee">www.etag.ee</a>                     | <p><b>Mr Argo SOON</b><br/>Estonian Research Council<br/>Soola 8<br/>51013 Tartu<br/>Estonia<br/>Tel: +372 7300 372<br/>E-mail: <a href="mailto:argo.soon@etag.ee">argo.soon@etag.ee</a></p>   |
| France                             | National Cancer Institute (INCa)                           | <a href="http://www.e-cancer.fr">www.e-cancer.fr</a>             | <p><b>Estelle GERBAUD, PharmD</b><br/>Research and Innovation Division<br/>52 avenue André Morizet<br/>92513 Boulogne Billancourt Cedex,<br/>France<br/>Tel: +33 (0)1 41 10 14 16<br/>E-mail: <a href="mailto:egerbaud@institutcancer.fr">egerbaud@institutcancer.fr</a></p>   |
|                                    | ARC French Foundation for Cancer Research (ARC Foundation) | <a href="http://www.fondation-arc.org">www.fondation-arc.org</a> | <p><b>Delphine FERRIER, PhD</b><br/>Translational Research &amp; Innovation -<br/>Fondation ARC pour la recherche sur le cancer<br/>9 Rue Guy Moquet – BP 90003 94803<br/>Villejuif Cedex, France Tel: +33 (0)1 45<br/>59 59 51<br/>E-mail: <a href="mailto:dferrier@fondation-arc.org">dferrier@fondation-arc.org</a></p>   |

|         |   |  |   |
|---------|---|--|---|
| Germany | Federal Ministry of Education and Research (BMBF) / PT-DLR  | <a href="http://www.gesundheitsforschung-bmbf.de">www.gesundheitsforschung-bmbf.de</a> | <p><b>Akin Akkoyun</b><br/>Project Management Agency of the German Aerospace Center (PT-DLR) - Health Research-Heinrich-Konen-Str. 1 D-53227 Bonn, Germany<br/>Tel: +49 (0)228/3821-1864<br/>Fax: +49 (0)228/3821-1257<br/>E-mail: <a href="mailto:akin.akkoyun@dlr.de">akin.akkoyun@dlr.de</a></p> <p><b>Hubert Misslisch</b><br/>Project Management Agency of the German Aerospace Center (PT-DLR) - Health Research-Heinrich-Konen-Str. 1 D-53227 Bonn, Germany<br/>Tel: +49 (0)228/3821-1271<br/>Fax: +49 (0)228/3821-1257<br/>E-mail: <a href="mailto:hubert.misslisch@dlr.de">hubert.misslisch@dlr.de</a></p> |
| Greece  | General Secretariat for Research and Technology, Ministry of Education, Research and Religious Affairs (GSRT) | <a href="http://www.gsrt.gr">www.gsrt.gr</a>   | <p><b>Sofia DIMITROPOULOU</b><br/>General Secretariat for Research &amp; Technology<br/>International S&amp;T Cooperation Directorate<br/>Division of Bilateral &amp; Multilateral Relations 14-18, Mesogeion Av., 11510 Athens, Greece<br/>Tel.: (+30) 210 7458187<br/>Fax: (+30) 210 7714153<br/>E-mail: <a href="mailto:s.dimitropoulou@gsrt.gr">s.dimitropoulou@gsrt.gr</a></p>   |
| Israel  | The Chief Scientist Office of the Ministry of Health (CSO-MOH)  | <a href="http://www.health.gov.il">www.health.gov.il</a>                               | <p><b>Dr. Ahmi BEN-YEHUDAH</b><br/>Director of Research Administration<br/>Chief Scientist Office<br/>Ministry of Health<br/>Israel<br/>Tel: +972-2-5082163<br/>E-mail: <a href="mailto:ahmi.by@MOH.HEALTH.GOV.IL">ahmi.by@MOH.HEALTH.GOV.IL</a></p> <p><b>Dr. Ayelet ZAMIR</b><br/>TRANSCAN-2 National Coordinator<br/>Chief Scientist Office<br/>Ministry of Health<br/>Israel<br/>Tel: +972-2-508-2168<br/>E-mail: <a href="mailto:ayelet.zamir@moh.gov.il">ayelet.zamir@moh.gov.il</a></p>  |

|        |  |  |   |
|--------|--|--|---|
| Italy  | Ministry of Health (MoH)                           | <a href="http://www.salute.gov.it">www.salute.gov.it</a>                         | <p><b>Dr. Gaetano GUGLIELMI</b><br/> Directorate General for Health Research and Innovation<br/> Ministry of Health – Ministero della Salute<br/> Viale Giorgio Ribotta, 5 00144 Rome, Italy<br/> Phone: +39 065994.3528<br/> E-mail: <a href="mailto:g.guglielmi@sanita.it">g.guglielmi@sanita.it</a></p> <p><b>Dr. Silvia PARADISI</b><br/> Directorate General for Health Research and Innovation<br/> Ministry of Health – Ministero della Salute<br/> Phone: +39 064990 6553<br/> E-mail: <a href="mailto:silvia.paradisi@iss.it">silvia.paradisi@iss.it</a></p> |
|        | Alliance Against Cancer (ACC)                      | <a href="http://www.alleanzacontroilcancro.it">www.alleanzacontroilcancro.it</a> | <p><b>Dr. Gennaro CILIBERTO</b><br/> Alliance Against Cancer<br/> Via Giorgio Ribotta 5, 00144 Rome, Italy<br/> Tel: +39 065994.3412<br/> Email: <a href="mailto:gennaro.ciliberto@ifo.gov.it">gennaro.ciliberto@ifo.gov.it</a></p> <p><b>Dr. Maddalena BARBA</b><br/> Alliance Against Cancer<br/> Via Giorgio Ribotta 5, 00144 Rome, Italy<br/> Tel: +39 065994.3412<br/> Email: <a href="mailto:maddalena.barba@gmail.com">maddalena.barba@gmail.com</a></p>   |
|        | Lombardy Foundation for Biomedical Research (FRRB) | <a href="http://www.frrb.it">www.frrb.it</a>                                     | <p><b>Mrs. Carmen De Francesco</b><br/> Via Taramelli 12, 20124 - Milano<br/> Tel: +39 02 67650170<br/> Email: <a href="mailto:carmen.defrancesco@frrb.it">carmen.defrancesco@frrb.it</a></p> <p><b>Dr. Chiara Antonella Cecchi</b><br/> Via Taramelli 12, 20124 - Milano<br/> Tel: +39 02 67650173<br/> Email: <a href="mailto:chiara.antonella.cecchi@frrb.it">chiara.antonella.cecchi@frrb.it</a></p>  |
| Latvia | State Education Development Agency (VIAA)          | <a href="http://www.viaa.gov.lv">www.viaa.gov.lv</a>                             | <p><b>Dr. Maija Bundule</b><br/> State Education Development Agency (VIAA)<br/> Valnu str. 1, LV-1050 Riga<br/> Tel: +371 – 67785423<br/> E-Mail: <a href="mailto:Maija.Bundule@viaa.gov">Maija.Bundule@viaa.gov</a></p> <p><b>Dr. Uldis Berkis</b><br/> State Education Development Agency (VIAA)<br/> Valnu str. 1, LV-1050 Riga<br/> Tel: +371 – 67785487<br/> Tel: +371 – 29472349<br/> E-Mail: <a href="mailto:Uldis.Berkis@viaa.gov.lv">Uldis.Berkis@viaa.gov.lv</a></p>  |

|                 |  |  |   |
|-----------------|--|--|---|
| the Netherlands | Dutch Cancer Society (DCS)                           | <a href="http://www.kwf.nl">www.kwf.nl</a>                         | <p><b>Miranda WIJDENES</b><br/>KWF Kankerbestrijding<br/>Delflandlaan 17<br/>Postbus 75508 1070 AM Amsterdam<br/>The Netherlands<br/>Tel: + 31 20 5700500<br/>Email: <a href="mailto:mwijdenes@kwf.nl">mwijdenes@kwf.nl</a></p>   |
| Norway          | The Research Council of Norway (RCN)                 | <a href="http://www.forskningsradet.no">www.forskningsradet.no</a> | <p><b>Karianne SOLAAS</b><br/>The Research Council of Norway,<br/>Division for Society and Health,<br/>Department for Health<br/>P.O Box 564 NO-1327 Lysaker<br/>E-mail: <a href="mailto:kso@rcn.no">kso@rcn.no</a> Tel: +47 94535380</p> <p><b>Henrietta BLANKSON</b><br/>The Research Council of Norway,<br/>Division for Society and Health,<br/>Department for Health<br/>P.O Box 564 NO-1327 Lysaker<br/>E-mail: <a href="mailto:hbl@rcn.no">hbl@rcn.no</a> Tel: + 47 92233762</p>   |
|                 | Norwegian Cancer Society (NCS)                       | <a href="http://www.kreftforeningen.no">www.kreftforeningen.no</a> | <p><b>Anita LYGSTADAAS</b><br/>Norwegian Cancer Society Postboks 4,<br/>Sentrum<br/>0101 Oslo Norway<br/>Tel: +47 466 38 484<br/>E-mail:<br/><a href="mailto:Anita.Lyngstadaas@kreftforeningen.no">Anita.Lyngstadaas@kreftforeningen.no</a></p>   |
| Poland          | National Centre for Research and Development (NCBiR) | <a href="http://www.ncbir.pl">www.ncbir.pl</a>                     | <p><b>Marcin CHMIELEWSKI</b><br/>Section for Research Projects BIOMED,<br/>ul. Nowogrodzka 47a, 00-695 Warszawa,<br/>Poland<br/>+48 22 39 07 109<br/><a href="mailto:marcin.chmielewski@ncbr.gov.pl">marcin.chmielewski@ncbr.gov.pl</a></p> <p><b>Robert LESIUK</b><br/>Section for Research Projects BIOMED,<br/>ul. Nowogrodzka 47a, 00-695 Warszawa,<br/>Poland<br/>+48 22 39 07 296<br/><a href="mailto:Robert.lesiuk@ncbr.gov.pl">Robert.lesiuk@ncbr.gov.pl</a></p>  |
| Slovakia        | Slovak Academy of Sciences (SAS)                     | <a href="http://www.sav.sk">www.sav.sk</a>                         | <p><b>Mr. Jan BARANCIK, PhD</b><br/>Department for International Cooperation of SAS,<br/>Slovak Academy of Sciences,<br/>Štefánikova 49<br/>814 38 - Bratislava, Slovak Republic<br/>Tel: +421 2 5751 0137<br/>E-mail: <a href="mailto:barancik@up.upsav.sk">barancik@up.upsav.sk</a></p> <p><b>Mr. Martin NOVAK, PhD</b><br/>Department for International Cooperation of SAS,<br/>Slovak Academy of Sciences,<br/>Štefánikova 49<br/>814 38 - Bratislava, Slovak Republic<br/>Tel: +421 2 5751 0179<br/>E-mail: <a href="mailto:mnovak@up.upsav.sk">mnovak@up.upsav.sk</a></p> |

|          |  |  |   |
|----------|--|--|---|
| Slovenia | Ministry of Education, Science and Sport (MIZS)  | <a href="http://www.mizs.gov.si/en/">www.mizs.gov.si/en/</a> | <b>Dr. Eva BATISTA</b><br>Directorate for Science MIZS<br>Masarykova 16<br>1000 Ljubljana, Slovenia<br>E-mail: <a href="mailto:eva.batista@gov.si">eva.batista@gov.si</a><br>Tel: + 386 1 478 4754  |
| Spain    | National Institute of Health Carlos III (ISCIII)   | <a href="http://www.isciii.es">www.isciii.es</a>             | <b>Elsa MOREDA</b><br>Deputy Directorate of International Programmes for Research and Institutional Relations<br>National Institute of Health Carlos III<br>Email: <a href="mailto:emoreda@isciii.es">emoreda@isciii.es</a><br>Tel.: +34 91 822 2874  |
|          | The Foundation for the support of the Applied Scientific Research and Technology in Asturias (FICYT) | <a href="http://www.ficyt.es">www.ficyt.es</a>               | <b>Inés Rey HIDALGO</b><br>Innovation Management Department<br>E-mail: <a href="mailto:inesrey@ficyt.es">inesrey@ficyt.es</a><br>Tel: +34 985 20 74 34  |
|          | Spanish Association Against Cancer Scientific Foundation (AECC FC)                                   | <a href="http://www.aecc.es">www.aecc.es</a>                 | <b>Dr. Marta PUYOL ESCOLAR</b><br>Fundación científica de la AECC<br>C/Amador de los ríos, 5<br>28010-Madrid<br>Tel: +34 91 3108207<br>Email: <a href="mailto:marta.puyol@aecc.es">marta.puyol@aecc.es</a>  |
| Taiwan   | Ministry of Science and Technology (MoST)  | <a href="http://www.most.gov.tw">www.most.gov.tw</a>         | <b>Dr. Louis CHEN</b><br>Ministry of Science and Technology (Taiwan) No. 106, Sec 2 Heping E. Road, Taipei, 106, Taiwan, R.O.C<br>Tel: +886-2-2737-7959<br>E-mail: <a href="mailto:ymchen@most.gov.tw">ymchen@most.gov.tw</a>   |
| Turkey   | The Scientific and Technological Research Council of Turkey (TÜBİTAK)                                | <a href="http://www.tubitak.gov.tr">www.tubitak.gov.tr</a>   | <b>Ms. A. Özge GÖZAY</b><br>TÜBİTAK ULAKBİM YÖK Binası B5<br>BLOK 06539 BİLKENT / Ankara, Turkey<br>Tel: + 90 312 298 9425<br>E-mail: <a href="mailto:ncphealth@tubitak.gov.tr">ncphealth@tubitak.gov.tr</a><br><br><b>Ms. Ayşenur OKATAN</b><br>TÜBİTAK ULAKBİM YÖK Binası B5<br>BLOK 06539 BİLKENT / Ankara, Turkey<br>Tel: + 90 312 298 9404<br>E-mail: <a href="mailto:ncphealth@tubitak.gov.tr">ncphealth@tubitak.gov.tr</a> |

## ANNEX 2. INDICATIVE FUNDING COMMITMENT OF THE FUNDING ORGANISATIONS PARTICIPATING IN TRANSCAN-2 JTC 2016

| Country/ Region                 | Participating funding organisation  | Envisioned amount of funding (Mio € for 3 years) | Anticipated number of fundable research groups |
|---------------------------------|---|--|--|
| Belgium: Flemish region         | Research Foundation - Flanders (FWO)  | 0,200  | 1  |
| Belgium: French speaking region | Fund for Scientific Research (FNRS)   | 0,200  | 1  |
| Estonia                         | Estonian Research Council (ETAg)  | 0,300  | 2  |
| France                          | National Cancer Institute (INCa)  | 1,500  | 5 – 10   |
|                                 | ARC French Foundation for Cancer Research (ARC Foundation)  | 0,500  | 1 – 3  |
| Germany                         | Federal Ministry of Education and Research (BMBF) / PT- DLR   | 3,000  | 10-12  |
| Greece                          | General Secretariat for Research and Technology, Ministry of Education, Research and Religious Affairs (GSRT) | 0,500  | Up to 5  |
| Israel                          | The Chief Scientist Office of the Ministry of Health (CSO-MOH)  | 0.210  | 2  |
| Italy                           | Ministry of Health (MoH)  | 3,000  | 10   |
|                                 | Alliance Against Cancer (ACC)   | 0,250  | 1-2  |
|                                 | Lombardy Foundation for Biomedical Research (FRRB)  | 1,000  | 2  |
| Latvia                          | State Education Development Agency (VIAA)   | 0,210  | 1  |
| the Netherlands                 | Dutch Cancer Society (DCS)  | 2,000  | 4-6  |
| Norway                          | The Research Council of Norway (RCN)  | 0,500  | 3  |
|                                 | Norwegian Cancer Society (NCS)  | 0,500  | 3  |
| Poland                          | National Centre for Research and Development (NCBiR)  | 0,500  | 1 – 3  |
| Slovakia                        | Slovak Academy of   | 0,210  | 1-2  |



|          |  |       |       |
|----------|--|-------|-------|
|          | Sciences (SAS)   |       |       |
| Slovenia | Ministry of Education, Science and Sport (MIZS)  | 0,210 | 1-2   |
| Spain    | National Institute of Health Carlos III (ISCIII)   | 0,150 | 1     |
|          | The Foundation for the support of the Applied Scientific Research and Technology in Asturias (FICYT) | 0,250 | 2     |
|          | Scientific Foundation Spanish Association Against Cancer (SF AECC)                                   | 0,250 | 1-2   |
| Taiwan   | Ministry of Science and Technology (MoST)  | 0,500 | 2-3   |
| Turkey   | The Scientific and Technological Research Council of Turkey (TÜBİTAK)                                | 0,350 | 2 – 3 |

### ANNEX 3. ELIGIBILITY OF BENEFICIARY INSTITUTIONS FOR THE FUNDING ORGANISATIONS PARTICIPATING IN TRANSCAN-2 JTC 2016

| Country/<br>Region                 | Participating<br>funding<br>organisation  | Eligible beneficiary institution <sup>(1)</sup>   |  |  |
|------------------------------------|---|---|--|--|
|                                    |   | Academia  | Clinical/ public<br>health                           | Enterprise   |
| Belgium: Flemish<br>region         | Research<br>Foundation -<br>Flanders (FWO)  | Yes   | No   | No   |
| Belgium: French<br>speaking region | Fund for Scientific<br>Research (FNRS)  | Yes   | No (except the<br>ISP-Institut de<br>Santé Publique) | No   |
| Estonia                            | Estonian<br>Research Council<br>(ETAg)  | Yes   | Yes  | Yes (if<br>requirements for<br>research staff are<br>fulfilled)  |
| France                             | National Cancer<br>Institute (INCa)   | Yes   | Yes  | No   |
|                                    | ARC French<br>Foundation for<br>Cancer Research<br>(ARC<br>Foundation)  |   |  |  |
| Germany                            | Federal Ministry<br>of Education and<br>Research<br>(BMBF) / PT-<br>DLR   | Yes   | Yes  | Yes  |
| Greece                             | General<br>Secretariat for<br>Research and<br>Technology,<br>Ministry of<br>Education,<br>Research and<br>Religious Affairs<br>(GSRT) | Yes   | Yes  | Yes  |
| Israel                             | The Chief<br>Scientist Office of<br>the Ministry of<br>Health (CSO-<br>MOH)   | Yes   | Yes  | No   |
| Italy                              | Ministry of Health<br>(MoH)   | No  | Yes  | No   |
|                                    | Alliance Against<br>Cancer (ACC)  | No  | Yes  | No   |
|                                    | Lombardy<br>Foundation for<br>Biomedical<br>Research (FRRB)   | Yes (in<br>partnership with<br>IRRCS or ASST)     | Yes (public and<br>Private IRCCS<br>and ASST)        | Yes (only SMEs<br>in partnership<br>with IRRCS and<br>ASST)      |
| Latvia                             | State Education<br>Development<br>Agency (VIAA)   | Yes, must be<br>listed in the<br>Latvian Registry | Only if listed into<br>the Latvian<br>Registry of    | Must be listed in<br>the Latvian<br>Commercial<br>Registry, have |

|                 |  | of Scientific institutions   | Scientific institutions   | resources and main activity incl. research activity in Latvia   |
|-----------------|--|--|---|---|
| the Netherlands | Dutch Cancer Society (DCS)   | Yes, according to grant conditions KWF Kankerbestrijding   | Yes, research institutes and university hospitals according to grant conditions KWF Kankerbestrijding   | No  |
| Norway          | The Research Council of Norway (RCN)   | Yes, please read <a href="#">link</a>  | Yes, please read <a href="#">link</a>   | No  |
|                 | Norwegian Cancer Society (NCS)   | Yes, please read <a href="#">link</a>  | Yes, please read <a href="#">link</a>   | No  |
| Poland          | National Centre for Research and Development (NCBiR)   | Yes, according to the Principles of Financing Science, published in Journal of Laws No. 96 item 616, 2010, Organization must be registered in Poland | Yes, according to the Principles of Financing Science, published in Journal of Laws No. 96 item 616, 2010 Organization must be registered in Poland | Yes, according to the Principles of Financing Science, published in Journal of Laws No. 96 item 616, 2010 Organization must be registered in Poland |
| Slovakia        | Slovak Academy of Sciences (SAS)   | yes  | no  | no  |
| Slovenia        | Ministry of Education, Science and Sport (MIZS)  | Yes (under indicated conditions in Annex 4)  | Yes (under indicated conditions in Annex 4)   | Yes (under indicated conditions in Annex 4)   |
| Spain           | National Institute of Health Carlos III (ISCIII)   | Yes, Only under the conditions specified in the national rules   | Yes   | No  |
|                 | The Foundation for the support of the Applied Scientific Research and Technology in Asturias (FICYT) | Yes, according to the regional call grant conditions   | No  | Yes, according to the regional call grant conditions  |
|                 | Scientific Foundation Spanish Association Against Cancer (AECC FC)                                   | Please refer annex 4   | Please refer annex 4  | Please refer annex 4  |
| Taiwan          | Ministry of Science and Technology (MoST)  | Yes  | Yes   | No  |
| Turkey          | The Scientific and   | Yes (under the conditions  | Yes (under the conditions   | Yes (only research SMEs   |

|  |  |   |   |  |
|--|--|---|---|--|
|  | Technological Research Council of Turkey (TÜBİTAK) | specified in the <a href="#">national rules</a> ) | specified in the <a href="#">national rules</a> ) | under the conditions specified in the <a href="#">national rules</a> ) |
|--|--|---|---|--|

Please note that the information on this table is only indicative. Applicants are encouraged to contact their [national/regional contact points](#) for further information.

<sup>(1)</sup> The eligibility of companies and institutions is subject to different regulations in the participating country/region. Further details regarding the eligible beneficiaries and other national eligibility criteria and requirements are available on the “Guidelines for Applicants” and the TRANSCAN website (<http://www.transcanfp7.eu/>).

## ANNEX 4. NATIONAL/REGIONAL REGULATIONS AND CONTACT INFORMATION

|  |   |
|--|---|
| <b>Country</b>   | <b>Belgium (Flanders)</b>   |
| <b>Funding organisation</b>  | Research Foundation Flanders (FWO)  |
| <b>National contact persons</b>  | <p>dr. Olivier Boehme<br/>Science Policy Advisor<br/>Tel. +32 2 550 15 45</p> <p>Toon Monbaliu<br/>Advisor Research Affairs<br/>Tel. +32 2 550 15 70<br/>E-mail: <a href="mailto:eranet@fwo.be">eranet@fwo.be</a></p>   |
| <b>National programme</b>  | Research Projects: <a href="http://www.fwo.be/en/fellowships-funding/research-projects/research-project/">http://www.fwo.be/en/fellowships-funding/research-projects/research-project/</a>  |
| <b>Funding commitment</b>  | 0,2 M €   |
| <b>Anticipated number of fundable project partners</b>                     | 1   |
| <b>Maximum funding per grant awarded to a project partner</b>              | 0,2 M €   |
| <b>Eligibility of projects</b>   | Refer to call text  |
| <b>Eligibility of a partner as a beneficiary institution</b>               | Art. 9 of the FWO-regulations on the regular research projects is applicable. In this article is stated who can apply as a supervisor or co-supervisor for a research project:<br><a href="http://www.fwo.be/en/fellowships-funding/research-projects/research-project/regulations-for-research-projects/">http://www.fwo.be/en/fellowships-funding/research-projects/research-project/regulations-for-research-projects/</a> |
| <b>Eligibility of principal investigator or other research team member</b> | Art. 9 of the FWO-regulations on the regular research projects is applicable. In this article is stated who can apply as a supervisor or co-supervisor for a research project:<br><a href="http://www.fwo.be/en/fellowships-funding/research-projects/research-project/regulations-for-research-projects/">http://www.fwo.be/en/fellowships-funding/research-projects/research-project/regulations-for-research-projects/</a> |
| <b>Eligibility of costs, types and their caps</b>                          | Funding money can be used for staff, consumables and infrastructure. The minimal and maximal amounts of money allowed per cost category, as applicable for the regular FWO-projects, are not applicable for the projects funded by FWO in ERA-NET.<br>Overhead is not an eligible cost. Notwithstanding, FWO pays the host institutions of a project 6% overhead on top of the funding amount.                                |
| <b>Submission of the proposal at the national level</b>                    | Submission of the proposal at the national/regional level is NOT necessary.   |
| <b>Further guidance</b>  | It is strongly advised to contact FWO before submission, this in order to verify the researchers' eligibility.  |

|  |   |
|--|---|
| <b>Country</b>   | <b>Belgium (French speaking community)</b>  |
| <b>Funding organisation</b>  | National Research Funds - FNRS  |
| <b>National contact persons</b>  | Dr. Arnaud Goolaerts<br>Science Advisor<br>Tel. +32 2 504 93 28<br>arnaud.goolaerts@frs-fnrs.be   |
| <b>National programme</b>  | Research Projects: <a href="http://www1.frs-fnrs.be/docs/Reglement-et-documents/">http://www1.frs-fnrs.be/docs/Reglement-et-documents/</a>  |
| <b>Funding commitment</b>  | 0,2 M €   |
| <b>Anticipated number of fundable project partners</b>                     | 1   |
| <b>Maximum funding per grant awarded to a project partner</b>              | 0,2 M €   |
| <b>Eligibility of projects</b>   | Refer to call text  |
| <b>Eligibility of a partner as a beneficiary institution</b>               | See the list of eligible institutions in our regular PDR calls: <a href="http://www1.frs-fnrs.be/docs/Reglement-et-documents/FRS-FNRS_REGL_PDR_FR.pdf">http://www1.frs-fnrs.be/docs/Reglement-et-documents/FRS-FNRS_REGL_PDR_FR.pdf</a>   |
| <b>Eligibility of principal investigator or other research team member</b> | <p>The applicant must be affiliated to a research institution from the Fédération Wallonie-Bruxelles. The applicant should also:</p> <ul style="list-style-type: none"> <li>• be a permanent researcher of FNRS (Chercheur qualifié, Maître de recherches or Directeur de recherches),</li> <li>• or hold a tenure track position (or an assimilated position including pending tenure track) within a research institution from the Fédération Wallonie-Bruxelles,</li> <li>• or be a permanent research staff member of a federal scientific institution including the Ecole Royale Militaire in which case he can act as a co-promotor only.</li> </ul> <p>The applicant should not have reached retirement at the starting date of the project. If the applicant reaches the age of retirement in the course of the project, he should precisely describe in the proposal how the handover will be managed.</p> <p>A single applicant may only participate once as a Coordinator in a consortium applying to this call.</p> |
| <b>Eligibility of costs, types and their caps</b>                          | <p>The maximum amount allocated per project is <b>200.000 EUR</b>. The following costs are eligible:</p> <ul style="list-style-type: none"> <li>• <b>Personnel:</b> <ul style="list-style-type: none"> <li>• Scientifique doctorant € 37.200/year</li> <li>• Scientifique non postdoctoral € 63.300/year</li> <li>• Scientifique postdoctoral € 73.800/year</li> </ul> </li> </ul>  |

|   |   |
|---|---|
|   | <ul style="list-style-type: none"> <li>• Technicien € 53.700 (full time/year) - € 27.200 (half time/year)</li> <li>• Chercheur temporaire postdoctoral € 47.600/year</li> </ul> <p>The categories « scientifique doctorant » and « chercheur temporaire postdoctoral » can only be Full time positions. The three other positions can be filled in either Full time or part-time.</p> <ul style="list-style-type: none"> <li>• <b>Equipment (max. 30.000 EUR/project)</b></li> <li>• <b>Running costs:</b> travel expenses; organisation of small scientific events in Belgium; consumables and the following support costs: <ul style="list-style-type: none"> <li>• Conception d'ouvrage</li> <li>• Réalisation de dictionnaire</li> <li>• Achat de livre</li> <li>• Encodage</li> <li>• Location de licence de logiciel</li> <li>• Inscription à un congrès</li> <li>• Ordinateur</li> <li>• Scannage</li> </ul> </li> </ul> <p>“Overhead” is not an eligible cost. If the project is selected for funding, these costs will be subject to a separate agreement between the institution of the beneficiary and the FNRS. General rules and regulations of FNRS apply: <a href="http://www.frs-fnrs.be">www.frs-fnrs.be</a></p> |
| <b>Submission of the proposal at the national level</b> | Submission of the proposal at the national/regional level is NOT necessary.   |
| <b>Further guidance</b>                                 | It is strongly advised to contact FNRS before submission, this in order to verify the researchers' eligibility.   |

|  |   |   |
|--|---|---|
| <b>Country</b>   | <b>Estonia</b>  |   |
| <b>Funding organisation</b>  | Estonian Research Council (ETAg)<br><a href="http://www.etag.ee">www.etag.ee</a>  |   |
| <b>National contact persons</b>  | <b>Mr Argo SOON</b><br>Estonian Research Council<br>Soola 8, 51013 Tartu<br>Estonia<br>Tel: +372 7300 372<br>E-mail: <a href="mailto:argo.soon@etag.ee">argo.soon@etag.ee</a>   | <b>Mr Aare IGNAT</b><br>Estonian Research Council<br>Tel: +372 731 7364<br>E-mail: <a href="mailto:aare.ignat@etag.ee">aare.ignat@etag.ee</a> |
| <b>National programme</b>  | Mobilitas Pluss   |   |
| <b>Funding commitment</b>  | 0.300 Mio. €  |   |
| <b>Anticipated number of fundable project partners</b>                     | 2   |   |
| <b>Maximum funding per grant awarded to a project partner</b>              | 150 000 €   |   |
| <b>Eligibility of projects</b>   | According to call text  |   |
| <b>Eligibility of a partner as a beneficiary institution</b>               | Legal bodies such as universities, research institutions, enterprises, NGOs and other, provided availability of research staff that meets eligibility criteria described below.   |   |
| <b>Eligibility of principal investigator or other research team member</b> | <p>The Principal Investigator is the researcher who is appointed to be responsible for the use of the grant for its specific purpose and for the productive realisation of the project. The principal investigator:</p> <ul style="list-style-type: none"> <li>• Must possess either the Estonian nationality or citizenship or be a permanent resident of Estonia.</li> <li>• Has an updated profile in the Estonian Research Information System (ETIS).</li> <li>• Has as a rule entered into an employment relationship with the Host Institution, which is the basis of the realisation of the grant project and through which the grant shall be allocated to the Principal Investigator.</li> <li>• Must be a holder of the doctoral degree of Estonia or an equivalent academic degree (both awarded by the deadline of submission of the grant application, at the latest).</li> <li>• Must have published within the last five years prior to the proposal's submission deadline at least three publications, which comply with the requirements of clauses 1.1 of the classification of publications of the ETIS, or at least five publications, which comply with the requirements of clauses 1.1, 1.2, 2.1 and 3.1 of the classification of publications of the ETIS; international patents are equalised with publications of clause 1.1.; the monographs are equalised to each author with three publications mentioned in clause 1.1 if the number of its authors is three or less. If the applicant has been on the parental leave or in the compulsory military service within these last five years, the deadline of the publication requirement shall be extended by the time stayed on the parental leave or compulsory military service</li> </ul> |   |



|   |   |
|---|---|
| <b>Eligibility of costs, types and their caps</b> | <ol style="list-style-type: none"> <li>1. A budget of proposal shall consist of the research expenses and the overhead costs, through which the grant project is to be carried out.</li> <li>2. The research expenses consist of personnel costs, travel costs, other direct costs and subcontracting costs. The expenses on research are clearly required to carry out the project and respectively identifiable. All eligible costs are set in the decree of Mobilitas Pluss.</li> <li>3. Double funding of activities already having contributions is not acceptable. If the project or parts of the project are already being funded from other sources or the Host Institution is currently applying for other funding for the same project, the Host Institution is required to provide this information.</li> <li>4. Only costs which have been made between the signature of the grant agreement and 31.12.2022 are eligible.</li> <li>5. Remuneration may only be paid out of the grant to the Principal Investigator and main participants in the project according to the time they participate in the grant project and their total salary cost.</li> <li>6. Travel costs cover expenses for transport, accommodation and daily allowances (except in case of internal travel).</li> <li>7. Subcontracting costs cover generally only additional or complementary tasks (e.g. costs for translation, analyses, etc.) to the third parties. Core project research tasks should not be subcontracted. Subcontracting costs may not exceed 10% of the total costs.</li> <li>8. Other direct costs are: <ol style="list-style-type: none"> <li>8.1. Consumables related to the project;</li> <li>8.2. Costs for publishing and dissemination of project results (fair distribution of costs between partner should be followed);</li> <li>8.3. Costs for organising the meetings/seminars/conferences (only in Estonia);</li> <li>8.4. Fees for participating in scientific forums and conferences;</li> <li>8.5. All other costs which are clearly required for the implementation of the project, are respectively identifiable and which comply with the eligible costs of the Mobilitas Pluss decree.</li> </ol> </li> <li>9. Overhead costs of the project are 15% of eligible direct personnel costs and should cover general expenses of the Host Institution and the Council. Two thirds (2/3) of the overhead will go to the Host Institution and one third (1/3) will be kept by the Council (for checking the compliance of the costs with the rules of the European Structural Funds).</li> <li>10. Costs for equipment and services intended for public use (copying machine or printer publicly used, phone bills, copying service, etc.) shall be covered from the overhead fee.</li> <li>11. Participants' personal expenses or expenses not directly related to the project are not eligible.</li> </ol> |
| <b>National phase</b>                             | Not required. Only the submission of the joint proposal is required.  |
| <b>Further guidance</b>                           | <p>Estonian Research Council funds basic and applied research in terms of Organisation of Research and Development Act.</p> <p>Proposals may be submitted by the Estonia based research and development institutions in terms of Organisation of Research and Development Act.</p>  |

|  |   |   |
|--|---|---|
| <b>Country</b>   | <b>France</b>   |   |
| <b>Funding organisations</b>   | <a href="#">National Cancer Institute (INCa)</a>  | <a href="#">ARC Foundation for Cancer Research (Foundation ARC)</a>   |
| <b>National contact persons</b>  | <b>For INCa:</b><br><b>Estelle GERBAUD, PharmD</b><br><b>Research and Innovation Division</b><br>52 avenue André Morizet<br>92513 Boulogne Billancourt Cedex<br>Email : <a href="mailto:egerbaud@institutcancer.fr">egerbaud@institutcancer.fr</a><br>Phone: + 33 (0)1 41 10 14 16  | <b>For ARC Foundation:</b><br><b>Delphine FERRIER, PhD</b><br><b>Translational Research &amp; Innovation</b><br>Fondation ARC pour la recherche sur le cancer<br>9 Rue Guy Môquet – BP 90003<br>94803 Villejuif Cedex, France<br>Tel : +33 (0)1 45 59 59 51<br>E-mail: <a href="mailto:dferrier@fondation-arc.org">dferrier@fondation-arc.org</a> |
| <b>National programme</b>  | French National Cancer Plan 2014-2019   |   |
| <b>Funding commitment</b>  | INCa: 1.5M euro   | ARC Foundation: 0.5M euro   |
| <b>Anticipated number of fundable project partners</b>                     | INCa : From 5 to 10 research teams  | ARC Foundation: From 1 to 3 research teams  |
| <b>Maximum funding per grant awarded to a project partner</b>              | INCa and ARC Foundation do not have a maximum funding per grant; the amount depends on the scientific and medical needs and should be justified in the requested budget. However it is highly recommended to respect the available budget and anticipated number of fundable research groups mentioned above.   |   |
| <b>Eligibility of projects</b>   | Please refer to the call text   |   |
| <b>Eligibility of a partner as a beneficiary institution</b>               | <ul style="list-style-type: none"> <li>- Public research institutions (university, EPST, EPIC, etc.)</li> <li>- Non-profit organisations (associations, foundations, etc.)</li> <li>- Hospitals or other health care providers (CHU, CRLCC, etc.)</li> </ul>  |   |
| <b>Eligibility of principal investigator or other research team member</b> | <p><i>Reminder: Each transnational consortium must nominate a coordinator from one of the JTC 2016 countries/region. The coordinator will be responsible for the internal scientific management and for the external representation towards the JCS and the CSC. Each consortium partner will be represented by one principal investigator, who will be the contact person for the respective national/regional funding organization.</i></p> <ul style="list-style-type: none"> <li>- Public research institutions (university, EPST, EPIC, etc.)</li> </ul> |   |

|  |  |
|--|--|
|  | <ul style="list-style-type: none"> <li>- Non-profit organisations (associations, foundations, etc.)</li> <li>- Hospitals or other health care providers (CHU, CRLCC, etc.)</li> </ul> <p><i>Please note that for the reason that a personal investment is necessary for the good progress of the project, the PI is not allowed to coordinate simultaneously more than 3 projects funded by INCa.</i></p>  |
| <p><b>Eligibility of costs, types Eligibility of costs, types and their caps</b></p> | <p><b>For the research project:</b></p> <ul style="list-style-type: none"> <li>- <u>Equipment</u>: up to 150 000 € including taxes per equipment; the total amount of the “equipment” expenses could not exceed a maximum of 30% of the total grant awarded</li> <li>- <u>Consumables and subcontracting</u></li> <li>- <u>Personnel costs</u> <ul style="list-style-type: none"> <li>• Salary costs for permanent staff may be included in the budget with the exception of civil servants</li> <li>• Please note that salary for PhD student is not eligible outside activities for capacity building.</li> </ul> </li> <li>- <u>Travel and accommodation</u>: only for the partner team members and for project management meetings; the total amount of the “Travel and accommodation” expenses could not exceed a maximum of 8% of the total grant awarded (Travel and accommodation costs to attend the intermediate and/or final TRANSCAN status symposium as specified in the Call text could be included in addition to the 8%)</li> <li>- <u>Indirect costs/overheads</u>: not eligible</li> </ul> <p><b>For the capacity building activities</b> (<u>Important reminder</u>: These additional expenses should be asked to specifically reach the objectives mentioned in the dedicated section of the application forms):</p> <ul style="list-style-type: none"> <li>- Part of salary costs for support staff (technician, engineer, etc)</li> <li>- Part of salary for scientist, physician, veterinarian or pharmacist (short term training, PhD student, post-doctoral fellowship)</li> <li>- Travel and accommodation for exchanges programme</li> </ul> <p>Costs for project management workshops and dissemination events such as symposium are not eligible in this section.</p> |
| <p><b>National phase</b></p>   | <p>Not required. Only the submission of the joint proposal is required.</p>  |
| <p><b>Further guidance</b></p>   | <p>Not applicable</p>  |

|   |  |
|---|--|
| <b>Country</b>  | <b>Germany</b>   |
| <b>Funding organisations</b>                                  | <a href="#">Federal Ministry of Education and Research (BMBF)</a>  |
| <b>National contact persons</b>                               | <b>Dr. Akin Akkoyun</b><br>German Aerospace Center<br>Project Management Agency   Health Research<br>Heinrich-Konen-Str. 5<br>53227 Bonn<br>Email : <a href="mailto:akin.akkoyun@dlr.de">akin.akkoyun@dlr.de</a><br>Phone: + 49 (0) 228 3821 1864                      |
| <b>National programme</b>                                     | German Health Research Programme   |
| <b>Funding commitment</b>                                     | 3.0 Mio Euro   |
| <b>Anticipated number of fundable project partners</b>        | From 10 to 12 research teams   |
| <b>Maximum funding per grant awarded to a project partner</b> | BMBF does not have a maximum funding per grant; the requested budget depends on the scientific needs and must be duly justified. However, it is highly recommended to respect the available budget and anticipated number of fundable research groups mentioned above. |
| <b>Eligibility of projects</b>                                | Please refer to the call text  |
| <b>Eligibility of a partner as a beneficiary institution</b>  | <ul style="list-style-type: none"> <li>- Public research institutions</li> <li>- Non-profit organisations (associations, foundations, etc.)</li> <li>- Hospitals or other health care providers</li> <li>- Enterprises</li> </ul>                                      |
| <b>Eligibility of costs, types and their caps</b>             | <ul style="list-style-type: none"> <li>- Personnel costs</li> <li>- Consumables and subcontracting</li> <li>- Equipment</li> <li>- Travel and accommodation</li> </ul>   |
| <b>National phase</b>   | Not required. Only the submission of the joint proposal is required.   |
| <b>Further guidance</b>                                       | Not applicable   |

|   |  |
|---|--|
| <b>Country / Region</b>   | <b>Greece</b>  |
| <b>Funding organisation</b>   | General Secretariat for Research and Technology (GSRT)<br><a href="http://www.gsrt.gr">www.gsrt.gr</a>   |
| <b>National Programme</b>   | <b>National Research and Innovation Strategy for Smart Specialization 2014-2020</b><br><a href="http://www.gsrt.gr/News/Files/New1034/Executive%20Summary-2015-09-17-v04.pdf">http://www.gsrt.gr/News/Files/New1034/Executive%20Summary-2015-09-17-v04.pdf</a>   |
| <b>National contact person</b>  | DIMITROPOULOU Sofia<br><a href="mailto:s.dimitropoulou@gsrt.gr">s.dimitropoulou@gsrt.gr</a><br>Tel. : 00302107458187   |
| <b>Funding commitment</b>   | 0.5 ME   |
| <b>Maximum funding per grant awarded to a project partner</b>                       | Up to 0,1 ME per consortium  |
| <b>Anticipated number of fundable research partners</b>                             | 5 projects tentatively envisaged to be funded  |
| <b>Eligibility of project duration</b>  | 36 months  |
| <b>Eligibility of a partner as a beneficiary institution</b>                        | All legal entities (public and private sector)   |
| <b>Eligibility criteria and funding (Legal/administrative/financial conditions)</b> | <p style="text-align: center;"><b>Aid for research and development projects</b></p> <p>1.The aided part of the research and development project shall completely fall within one or more of the following categories:<br/>(a) fundamental research;<br/>(b) industrial research;<br/>(c) experimental development;</p> <p>2. The eligible costs of research and development projects shall be allocated to a specific category of research and development and shall be the following:<br/>(a) personnel costs: researchers, technicians and other supporting staff to the extent employed on the project;<br/>(b) costs of instruments and equipment to the extent and for the period used for the project. Where such instruments and equipment are not used for their full life for the project, only the depreciation costs corresponding to the life of the project, as calculated on the basis of generally accepted accounting principles are considered as eligible.<br/>(c) Costs for of buildings and land, to the extent and for the duration period used for the project. With regard to buildings, only the depreciation costs corresponding to the life of the project, as calculated on the basis of generally accepted accounting principles are considered as eligible. For land, costs of commercial transfer or actually incurred capital costs are eligible.</p> |

(d) costs of contractual research, knowledge and patents bought or licensed from outside sources at arm's length conditions, as well as costs of consultancy and equivalent services used exclusively for the project;  
 (e) additional overheads and other operating expenses, including costs of materials, supplies and similar products, incurred directly as a result of the project;

3. The aid intensity for each beneficiary :

- (a) 100 % of the eligible costs for fundamental research;
- (b) 50 % of the eligible costs for industrial research;
- (c) 25 % of the eligible costs for experimental development;

4. The aid intensities for industrial research and experimental development may be increased up to a maximum aid intensity of 80 % of the eligible costs as follows:

- (a) by 10 percentage points for medium-sized enterprises and by 20 percentage points for small enterprises;
- (b) by 15 percentage points if one of the following conditions is fulfilled:

(i) the project involves effective collaboration:

— between undertakings among which at least one is an SME, or is carried out in at least two Member States, or in a Member State and in a Contracting Party of the EEA Agreement, and no single undertaking bears more than 70 % of the eligible costs, or — between an undertaking and one or more research and knowledge-dissemination organisations, where the latter bear at least 10 % of the eligible costs and have the right to publish their own research results;

(ii) the results of the project are widely disseminated through conferences, publication, open access repositories, or free or open source software.

#### **Innovation aid for SMEs**

1. The eligible costs shall be the following:

- (a) costs for obtaining, validating and defending patents and other intangible assets;
- (b) costs for secondment of highly qualified personnel from a research and knowledge-dissemination organization or a large enterprise, working on research, development and innovation activities in a newly created function within the beneficiary and not replacing other personnel;
- (c) costs for innovation advisory and support services;

2. The aid intensity shall not exceed 50 % of the eligible costs.

3. In the particular case of aid for innovation advisory and support services the aid intensity can be increased up to 100 % of the eligible costs provided that the total amount of aid for innovation advisory and support services does not exceed EUR 100.000 per undertaking within any three year period.

#### **Aid for process and organisational innovation**

1. Aid to large undertakings shall only be compatible if they effectively collaborate with SMEs in the aided activity and the collaborating SMEs incur at least 30 % of the total eligible costs.

2. The eligible costs shall be the following:

|   |   |
|---|---|
|   | <p>(a) personnel costs;</p> <p>(b) costs of instruments, equipment to the extent and for the period used for the project. Where such instruments and equipment are not used for their full life for the project, only the depreciation costs corresponding to the life of the project, as calculated on the basis of generally accepted accounting principles are considered as eligible.</p> <p>(c) costs of contractual research, knowledge and patents bought or licensed from outside sources at arm's length conditions;</p> <p>(d) additional overheads and other operating costs, including costs of materials, supplies and similar products, incurred directly as a result of the project.</p> <p>3. The aid intensity shall not exceed 15 % of the eligible costs for large undertakings and 50 % of the eligible costs for SMEs.</p> <p>Further information regarding the categorization of aid intensity is available at the national guide published at GSRT website.</p> <p><i>Eligible costs as Indirect costs</i></p> <p>Up to 5% of the total budget.</p> <p><u>Upper funding limits for the eligible costs</u></p> <p>The Upper limit of the total public funding will be 100.000 € per project. The maximum state aid intensity will be calculated according to the provisions of the European state aid rules and regulations in force (type of research activity, size of the participating enterprise, collaborative research).</p> |
| <b>Submission of the proposal at the national level</b> | After the selection of the projects at European level a national call will be launched for the submission of the approved proposals at national level in order to be funded by GSRT .   |
| <b>Further guidance</b>                                 | For more information please contact the indicated NCP for the current call  |

|  |   |
|--|---|
| <b>Country</b>   | <b>Israel</b>   |
| <b>Funding organisation</b>  | CSO-MOH<br><a href="http://www.health.gov.il/Subjects/research/International_cooperations/Pages/default.aspx">http://www.health.gov.il/Subjects/research/International_cooperations/Pages/default.aspx</a>  |
| <b>National contact persons</b>  | <b>Dr. Ahmi Ben-Yehudah</b><br>E-mail: <a href="mailto:ahmi.by@moh.gov.il">ahmi.by@moh.gov.il</a>   |
| <b>National programme</b>  | Medical Research Administration   |
| <b>Funding commitment</b>  | Up to 0.21 Mio €  |
| <b>Anticipated number of fundable project partners</b>                     | Up to 2   |
| <b>Maximum funding per grant awarded to a project partner</b>              | Up to 100,000 €<br>An additional 10,000 Euros will be granted if the Israeli researcher is the coordinator  |
| <b>Eligibility of projects</b>   | Bio-Medical research at large   |
| <b>Eligibility of a partner as a beneficiary institution</b>               | Position in a university, research center or hospital. Research authority must approve position prior to submission   |
| <b>Eligibility of principal investigator or other research team member</b> | PI should hold a Ph.D., M.D., D.M.D. or equivalent degree and employed by an eligible institution. Research will not be funded simultaneously by CSO-MOH on more than one grant (ERA-NET or national). Researchers can not apply for more than one grant from any ERA-NET funded by CSO-MOH or submit more than one proposal for any single program.  |
| <b>Eligibility of costs, types and their caps</b>                          | Personnel (students, technicians. applicants excluded); Animal, Materials and consumables; Travel (up to 10%); Institutional overhead 10%. No permanent equipment.  |
| <b>National phase</b>  | Prior to submission, researchers must submit to CSO-MOH an abstract approved by their research authority including detailed budget distribution. This is not the consortia abstract, but an abstract describing the activity of the Israeli researcher within the consortia. No submission of abstract can lead to disqualification of the whole application, as well as the consortium.<br>Bioethics approvals, if applicable should be submitted with the application or within 4 months later.<br>Submission of financial and scientific reports at the national level is required annually. |
| <b>Further guidance</b>  | Please see detailed instruction at:<br><a href="http://www.health.gov.il/Subjects/research/International_cooperations/Pages/default.aspx">http://www.health.gov.il/Subjects/research/International_cooperations/Pages/default.aspx</a>  |



|  |  |
|--|--|
| <b>Country</b>   | <b>ITALY</b>   |
| <b>Funding organisation</b>  | Ministry of Health (Ministero della Salute)<br>www.salute.gov.it   |
| <b>National contact persons</b>  | <p><b>Dr. Gaetano GUGLIELMI</b><br/>Directorate General for Health Research and Innovation<br/>Ministry of Health – Ministero della Salute<br/>Viale Giorgio Ribotta,5<br/>00144 Rome, Italy<br/>Phone: +39065994.3528<br/>E-mail: g.guglielmi@sanita.it</p> <p><b>Dr. Silvia PARADISI</b><br/>Directorate General for Health Research and Innovation<br/>Ministry of Health – Ministero della Salute<br/>Phone: +39 064990 6553<br/>E-mail: silvia.paradisi@iss.it</p>  |
| <b>National programme</b>  | <b>Framework National Programme "Health Research" of the Ministry of Health.</b>   |
| <b>Funding commitment</b>  | € 3 Mio  |
| <b>Anticipated number of fundable project partners</b>                     | 10   |
| <b>Maximum funding per grant awarded to a project partner</b>              | € 300.000,00   |
| <b>Eligibility of projects duration</b>                                    | Max 3 years  |
| <b>Eligibility of a partner as a beneficiary institution</b>               | <p><b>ONLY IRCCS:</b> Scientific Institutes for Research, Hospitalization and Health Care (Istituti di Ricovero e Cura a Carattere Scientifico pubblici e privati).</p> <p><b>Non fundable:</b> University, research institutes.</p>   |
| <b>Eligibility of principal investigator or other research team member</b> | <p>The simultaneous participation in proposals submitted in 2017 to different transnational research calls, funded by the Ministero della Salute, is not allowed to Italian Principal Investigators or other research team members.</p> <p>In order to expedite the eligibility check process, the Ministry of Health will grant an eligibility clearance to the applicants prior to the submission of the proposals. To this end, it is mandatory that the applicants fill out and return a <a href="#">pre-eligibility check form</a> through IRCCS Scientific Directorate using WFR System before submitting their proposals to the Joint Call Secretariat. It is strongly recommended that the form,</p> |

|   |  |
|---|--|
|   | completed and duly signed, is returned at <b>least 10 working days before</b> the proposal submission deadline. Applicants will be sent a written notification of their eligibility status.  |
| <b>Eligibility of costs, types and their caps</b> | <p><b>Direct Costs:</b><br/> Personnel (only temporary contracts) (max 50%);<br/> Consumables;<br/> Animals;<br/> Subcontracts (Max 20%);<br/> Equipment (only on hire);<br/> Travel (max 10%);<br/> Documentation (Max 1%)</p> <p><b>Indirect Costs:</b><br/> Overhead (max 10%);<br/> <b>other indirects cost aren't eligible</b></p>  |
| <b>National phase<br/>Further guidance</b>        | <p>After the TRANSCAN-2 JTC 2016 peer review process has been completed and the final (scientific) ranking list has been established and endorsed by the Call Steering Committee, the Ministry of Health will invite the principal investigators of the projects approved for funding to enter the formal national negotiations (according to national regulations).<br/> Submission of annual scientific and financial reports at the national level will be required according to the rules of the Ministry of Health.</p> <p>Further information on the rules of the Ministry of Health can be found at <a href="http://www.salute.gov.it">http://www.salute.gov.it</a>, section "Ricerca Sanitaria", or requested to the national contact persons.</p> |

|   |   |
|---|---|
| <b>Country</b>  | <b>Italy</b>  |
| <b>Funding organisation</b>   | Alliance Against Cancer (ACC)   |
| <b>National contact persons</b>   | Prof. Gennaro Ciliberto<br>Tel +390659943412<br>email gennaro.ciliberto@ifp.gov.it<br><br>Dr Maddalena Barba<br>Tel. +390659943412<br>email maddalena.barba@gmail.it  |
| <b>National programme</b>   | Framework National Programme “Health Research” of the Italian Ministry of Health  |
| <b>Funding commitment</b>   | 0.250 M €   |
| <b>Anticipated number of fundable project partners</b>  | 1-2   |
| <b>Maximum funding per grant awarded to a project partner</b>                                 | 0.125 M €   |
| <b>Eligibility of projects</b>  | Please refer to the call text   |
| <b>Eligibility of a partner as a beneficiary institution</b>                                  | Based on the D.Legs 229/99, eligible partners will be Hospitalization and Health Care Institutes, i.e., Istituti di Ricovero e Cura a Carattere Scientifico, IRCCS, pubblici e private. The following will be not fundable: Universities, research institutions other than the aforementioned, companies.   |
| <b>Eligibility of principal investigator or other research team member</b>                    | In full agreement with the internal procedures, Regional Foundation for Biomedical Research (FRRB) will grant an eligibility clearance to the potential applicants prior to the submission of the pre-proposals. The eligibility check will be based on the use of dedicated forms (available on the institutional web-site) to be returned to the FRRB's Contact Person in their completed and duly signed version at least 10 working days before the pre-proposal submission deadline. The eligibility status will be notified by written communication. |
| <b>Eligibility of costs, types and their caps</b>   | Only costs generated over the lifetime of the project will be considered eligible. Personnel (only temporary contracts) (50%); Consumables; Animals; Subcontractors (max 20%); Equipment (only on hire); Travels (max 10%); Overheads (max 10%); Publications (max 1%); Travel expenses and subsistence allowances related to training activities of the projects.  |
| <b>For the research project as well as for the capacity building and training activities:</b> | Once a definitive ranking list will be generated and endorsed by the Call Steering Committee, the coordinators and principal investigators of the projects granted for funding will enter the formal national negotiation (in agreement with the national regulation). Annual scientific and financial reports at the national level will be required.  |
| <b>National phase<br/>Further guidance</b>  | Further details will be provided by the national contact persons upon request.  |

|  |  |
|--|--|
| <b>Country</b>   | <b>Italy - Lombardy</b>  |
| <b>Funding organisation</b>  | Regional Foundation for Biomedical Research (FRRB)   |
| <b>National contact persons</b>  | <p><b>Carmen De Francesco</b><br/> <b>Address:</b> Via Taramelli 12, 20124 - Milano<br/> <b>Tel:</b> +39 02 67650170<br/> <b>Email:</b> <a href="mailto:carmen.defrancesco@frrb.it">carmen.defrancesco@frrb.it</a></p> <p><b>Chiara Antonella Cecchi</b><br/> <b>Address:</b> Via Taramelli 12, 20124 - Milano<br/> <b>Tel:</b> +39 02 67650173<br/> <b>Email:</b> <a href="mailto:chiara.antonella.cecchi@frrb.it">chiara.antonella.cecchi@frrb.it</a></p>  |
| <b>Regional programme</b>  | Regional Action Plan for the Biomedical Research – Year 2016   |
| <b>Funding commitment</b>  | 1 M €  |
| <b>Anticipated number of fundable project partners</b>                     | 2  |
| <b>Maximum funding per grant awarded to a project partner</b>              | 0.500 M €  |
| <b>Eligibility of projects</b>   | Please refer to the call text  |
| <b>Eligibility of a partner as a beneficiary institution</b>               | Public or Private <b>IRCCS</b> (Italian Scientific Institutes for Health Research and Health Care), Health Care Providers ( <b>ASST</b> ), Universities, Research Institutes, SMEs <u>located in the Lombardy territory</u> . It is <b>COMPULSORY</b> that at least one IRCCS (public or private) or ASST is partner of the funded project. Other types of organisations are eligible <b>ONLY</b> if in partnership with the IRCCS and ASST.   |
| <b>Eligibility of principal investigator or other research team member</b> | In full agreement with the organisational procedures, Regional Foundation for Biomedical Research (FRRB) will grant an eligibility clearance to the potential applicants prior to the submission of the pre-proposals. The eligibility check will be based on the use of dedicated forms to be returned to the Joint Call Secretariat in their completed and duly signed version at least 10 working days before the pre-proposal submission deadline. The eligibility status will be notified by written communication. |
| <b>Eligibility of costs, types and their caps</b>                          | <p>Only costs generated over the lifetime of the project will be considered eligible.</p> <p>Types of eligible costs: <b>Personnel</b> (in case of public IRCCS and ASST <b>ONLY</b> temporary contracts) (max 50% of direct costs); <b>Consumables</b>; <b>Animals</b>; <b>Subcontractors</b> (max 20%); <b>Equipment</b> (on hire or eligible amortisation rate); <b>Travels</b> (Travel expenses and subsistence allowances related to training</p>   |

|   |  |
|---|--|
|   | activities of the projects) (max 10%); <b>Overheads</b> (flat rate 20%, calculated on the basis of direct costs - Subcontracts are excluded from this calculation); <b>Publications</b> (max 5%);  |
| <b>For the research project as well as for the capacity building and training activities:</b> | Once a definitive ranking list will be generated and endorsed by the Call Steering Committee, the coordinators and principal investigators of the projects granted for funding will enter the formal national/regional negotiation (in agreement with the national regulation). Annual scientific and financial reports at the national/regional level will be required. |
| <b>National (regional) phase<br/>Further guidance</b>   | Administrative and Financial guidelines will be provided by FRRB to the contact persons of the funded organisations.   |

|  |  |
|--|--|
| <b>Country</b>   | <b>Latvia</b>  |
| <b>Funding organisation</b>  | Valsts izglītības attīstības aģentūra  |
| <b>National contact persons</b>  | <p><b>Dr. Maija BUNDULE</b><br/>Tel: +371 67785423<br/>E-mail: <a href="mailto:majja.bundule@viaa.gov.lv">majja.bundule@viaa.gov.lv</a></p> <p><b>Dr. Uldis BERKIS</b><br/>Tel: +371 29472349<br/>E-mail: <a href="mailto:uldis.berkis@viaa.gov.lv">uldis.berkis@viaa.gov.lv</a></p> <p>Valsts izglītības attīstības aģentūra<br/>Vaļņu iela 1, LV-1050 Rīga</p>   |
| <b>National programme</b>  | Support is provided according to Provisions Nr 259, 26.05.2015 of the Latvian Cabinet of Ministers <a href="http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibai-starptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma">http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibai-starptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma</a> Limitations and requirements of these provisions apply without exceptions.                                |
| <b>Funding commitment</b>  | 210.000 €  |
| <b>Anticipated number of fundable project partners</b>                     | 1  |
| <b>Maximum funding per grant awarded to a project partner</b>              | 210 TEUR (max 70 TEUR / year)  |
| <b>Eligibility of projects</b>   | The projects should correspond to the priorities of the TRANSCAN Call. Duration of the project - up to 3 years. The activities must correspond to “research” according to Latvian Law on Scientific Activity.  |
| <b>Eligibility of a partner as a beneficiary institution</b>               | Legal bodies: universities, state research institutes, other research institutions: should be listed in the Latvian register of research institutions. Enterprises entered into the Latvian Commercial registry are eligible, assumed they are eligible to do the specific research and can prove possession of research resources in Latvia, and their main activity incl. research activity is in Latvia. Limitations of EU legislation apply (R 651/2014) together with financial reporting requirements. |
| <b>Eligibility of principal investigator or other research team member</b> | Principal investigator – researcher holding a doctoral degree and experienced in the field related to the project thematic. Other research team members - researchers, physicians, technicians, assistants and supporting staff.   |
| <b>Eligibility of costs, types and their caps</b>                          | Project eligible costs are as follows:<br><b>For the research project:</b>   |

|                         |   |
|-------------------------|---|
|                         | <ol style="list-style-type: none"> <li>1. Personnel costs (researchers, technicians and other supporting staff to the extent employed on the research project) and relevant personnel taxes, maximum rates must be respected,</li> <li>2. Other direct costs such as consumables, equipment (only depreciation costs), reagents, animals,</li> <li>3. Subcontracting (up to 25% of total direct costs), with justification, includes also external patents and licenses and all external services,</li> <li>4. Travels and allowances,</li> <li>5. Overheads can reach a maximum of 25% of the direct project costs exempt subcontracting, and must be able shown to include only indirect cost categories</li> </ol> <p><b>For the capacity building and training activities:</b></p> <ol style="list-style-type: none"> <li>1. Short term training related to the project needs – covering possible only to direct travel costs.</li> </ol> <p>Core activities cannot be subcontracted.</p> |
| <b>National phase</b>   | <p>No special national procedures in application phase<br/>         In the contract phase annual scientific and financial reports will be required. Final research project cost statement must be audited by a dedicated auditor. Ethics and regulatory permissions are responsibility of the consortium.</p> <p><b>Latvian legislation requires conclusion of Consortium Agreement in order Latvian partner to be fundable.</b></p>  |
| <b>Further guidance</b> | <p><a href="http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibai-starptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma">http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibai-starptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma</a></p>  |

|   |  |
|---|--|
| <b>Country</b>  | <b>THE NETHERLANDS</b>   |
| <b>Funding organisation</b>   | <a href="#">Dutch Cancer Society (DCS / KWF Kankerbestrijding)</a>   |
| <b>National contact persons</b>   | <b>Dr. Miranda Wijdenes:</b> tel: +31-20-7545657; email: mwijdenes@kwf.nl  |
| <b>National programme</b>   | -  |
| <b>Funding commitment</b>   | € 2 Mio  |
| <b>Anticipated number of fundable project partners</b>  | 6 – 10   |
| <b>Maximum funding per grant awarded to a project partner</b>                                 | DCS does not have a maximum funding per grant; the amount depends on the scientific and medical needs and should be justified in the requested budget. However it is recommended to respect the available budget and anticipated number of fundable research groups mentioned above (including funding for capacity building and training activities). |
| <b>Eligibility of projects</b>  | Please refer to the call text.   |
| <b>Eligibility of a partner as a beneficiary institution</b>                                  | Please refer to the terms and conditions of KWF Kankerbestrijding on our <a href="#">website</a>   |
| <b>Eligibility of principal investigator or other research team member</b>                    | Please refer to the terms and conditions of KWF Kankerbestrijding on our <a href="#">website</a>   |
| <b>Eligibility of costs, types and their caps</b>   | -  |
| <b>For the research project as well as for the capacity building and training activities:</b> | Please refer to the terms and conditions of KWF Kankerbestrijding on our <a href="#">website</a><br>NB. Overhead costs are not eligible for funding.   |
| <b>National phase<br/>Further guidance</b>  | The official call announcement will be published on the KWF Kankerbestrijding <a href="#">website</a> ; applicants are strongly advised to contact the national contact persons.   |



|   |   |
|---|---|
| <b>Country</b>  | <b>Norway</b>   |
| <b>Funding organisation</b>   | NCS and RCN   |
| <b>National contact persons</b>   | <b>Anita Lyngstadaas (Anita.Lyngstadaas@kreftforeningen.no) and Karianne Solaas (kso@rcn.no)</b>  |
| <b>National programme</b>   | <b><i>For RCN:</i></b> Research Programme on High-quality and Reliable Diagnostics, Treatment and Rehabilitation (BEHANDLING)<br><b><i>For NCS:</i></b> -   |
| <b>Funding commitment</b>   | 1 mill. €   |
| <b>Anticipated number of fundable project partners</b>  | 3   |
| <b>Maximum funding per grant awarded to a project partner</b>                                 | 300.000 € in total to the Norwegian partners in one project. If one of the Norwegian researchers is coordinating the project, the Norwegian part may apply up to 400.000 €.   |
| <b>Eligibility of projects</b>  | Translational studies allowing a rapid implementation into public health-related decisions or into the clinic are encouraged  |
| <b>Eligibility of a partner as a beneficiary institution</b>                                  | Norwegian universities, university colleges, hospitals, independent research institutes and other publicly funded research groups. Private industry is not eligible.  |
| <b>Eligibility of principal investigator or other research team member</b>                    | The project manager/PI should have completed a doctoral degree or have corresponding qualifications.  |
| <b>Eligibility of costs, types and their caps</b>   | <b><i>For the research project:</i></b> Payroll expenses, grants/fellowships, procurement of R&D services, consumables, network measures<br><b><i>For the capacity building activities:</i></b> Salary of temporary staff with a specific expertise, short term training, PhD, Post-doctoral fellowship, Exchange programme<br>Indirect costs/overhead will be covered by the Research Council of Norway. |
| <b>For the research project as well as for the capacity building and training activities:</b> | -   |
| <b>National phase Further guidance</b>  | -   |

|  |   |
|--|---|
| <b>Country</b>   | <b>POLAND</b>   |
| <b>Funding organisation</b>  | National Centre for Research and Development (NCBR)<br>( <a href="http://www.ncbr.pl">http://www.ncbr.pl</a> )  |
| <b>National contact persons</b>  | Robert Lesiuk<br>Section for Research Projects BIOMED,<br>+48 22 39 07 109,<br>e-mail: robert.lesiuk@ncbr.gov.pl<br><br>Marcin Chmielewski<br>Section for Research Projects BIOMED,<br>+48 22 39 07 109,<br>e-mail: marcin.chmielewski@ncbr.gov.pl  |
| <b>National programme</b>  | National Scientific Research Programme ( <i>Krajowy Program Badań</i> )   |
| <b>Funding commitment</b>  | 0,5 M €   |
| <b>Anticipated number of fundable project partners</b>   | 1 - 3   |
| <b>Maximum funding per grant awarded to a project partner</b>  | The maximum cost should not exceed 0,25 M € for each Polish partner in the project.   |
| <b>Eligibility of projects</b>   | All proposals must be aligned with National regulations, inter alia: <ul style="list-style-type: none"> <li>• The Act of 30 April 2010 on the Principles of Financing Science, published in Journal of Laws No. 96 item 615, 2010;</li> <li>• The Act of 30 April 2010 on the National Centre for Research and Development, published in Journal of Laws No. 96 item 616, 2010;</li> </ul>  |
| <b>Eligibility of a partner as a beneficiary institution</b><br><b>Eligibility of principal investigator or other research team member</b>         | Following entities are eligible to apply: <ul style="list-style-type: none"> <li>• Research organizations</li> <li>• Micro, Small, Medium and Large Enterprise</li> <li>• Research consortia (according to The Act of 30 April 2010 on the Principles of Financing Science, published in Journal of Laws No. 96 item 615, 2010)</li> </ul> <p>Organization must be registered in Poland.</p>  |
| <b>Eligibility of costs, types and their caps</b><br><b>For the research project as well as for the capacity building and training activities:</b> | The eligible costs shall be the following: <ol style="list-style-type: none"> <li>1. <b>personnel costs</b> (researchers, technicians and other supporting staff to the extent employed on the research project);</li> <li>2. <b>costs of instruments and equipment, technical knowledge and patents</b> to the extent and for the period used for the research project; if such instruments and equipment are not used for their full life for the research project, only the depreciation costs corresponding to the life of the research project, as calculated on the basis of good accounting practice, shall be considered eligible;</li> </ol> |

|  | <p>3. <b>costs for buildings and land</b>, to the extent and for the duration used for the research project; with regard to buildings, only the depreciation costs corresponding to the life of the research project, as calculated on the basis of good accounting practice shall be considered eligible; for land, costs of commercial transfer or actually incurred capital costs shall be eligible;</p> <p>4. <b>cost of contractual research</b>, costs of consultancy and equivalent services used exclusively for the research activity; this cost type cannot account for more than 70% of all eligible costs of a project; the subcontracting can be obtained from consortium partner only in justified case, this need will be verified by a national experts panel;</p> <p>5. <b>other operating costs</b> including costs of materials, supplies and similar products, training activities incurred directly as a result of the research activity;</p> <p>6. <b>additional overheads</b> incurred indirectly as a result of the research project; that costs cannot account for more than <b>25%</b> of eligible project costs; That costs (6) are counted as a multiplication by percentage given above (called x%) and the rest of direct costs, excluding subcontracting (4); It means <math>6=(1+2+3+5)*x\%</math>.</p>  |                           |                           |   |                   |   |                                   |   |   |   |   |                                    |                        |                           |                           |             |                                 |                        |                           |                           |             |
|--|--|---------------------------|---------------------------|---|-------------------|---|-----------------------------------|---|---|---|---|------------------------------------|------------------------|---------------------------|---------------------------|-------------|---------------------------------|------------------------|---------------------------|---------------------------|-------------|
| <p><b>National phase</b><br/><b>Further guidance</b></p> | <p>Polish Participants will be informed and invited to submit Polish proposal once the international evaluation and the ranking list will be established.</p>  |                           |                           |   |                   |   |                                   |   |   |   |   |                                    |                        |                           |                           |             |                                 |                        |                           |                           |             |
| <p><b>National funding rates</b></p>                     | <p>Funding quota of Polish participants can be up to 100% for universities or research organisations. In the case of enterprises, funding quota will be decided on a case-by-case basis depending on the size of the company, type of research/development, risk associated with the research activities and commercial perspective of exploitation. Organization must be registered in Poland</p> <table border="1" data-bbox="725 738 2136 1155"> <thead> <tr> <th></th> <th>Large Enterprises</th> <th>Medium Enterprises</th> <th>Small Enterprises</th> <th>Universities and research organizations</th> </tr> </thead> <tbody> <tr> <td><b>Fundamental/Basic Research</b></td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Industrial/Applied Research</b></td> <td>Up to 50+15 (max 65 %)</td> <td>Up to 50+10+15 (max 75 %)</td> <td>Up to 50+20+15 (max 80 %)</td> <td>Up to 100 %</td> </tr> <tr> <td><b>Experimental development</b></td> <td>Up to 25+15 (max 40 %)</td> <td>Up to 25+10+15 (max 50 %)</td> <td>Up to 25+20+15 (max 60 %)</td> <td>Up to 100 %</td> </tr> </tbody> </table> <p>In any case only Industrial/Applied Research and Experimental Development will be funded. Other type of activities (e.g. coordination, dissemination, management) is not eligible for funding as separate research tasks in the project schedule.</p> |                           | Large Enterprises         | Medium Enterprises                      | Small Enterprises | Universities and research organizations | <b>Fundamental/Basic Research</b> | - | - | - | - | <b>Industrial/Applied Research</b> | Up to 50+15 (max 65 %) | Up to 50+10+15 (max 75 %) | Up to 50+20+15 (max 80 %) | Up to 100 % | <b>Experimental development</b> | Up to 25+15 (max 40 %) | Up to 25+10+15 (max 50 %) | Up to 25+20+15 (max 60 %) | Up to 100 % |
|  | Large Enterprises  | Medium Enterprises        | Small Enterprises         | Universities and research organizations |                   |   |                                   |   |   |   |   |                                    |                        |                           |                           |             |                                 |                        |                           |                           |             |
| <b>Fundamental/Basic Research</b>                        | -  | -                         | -                         | -                                       |                   |   |                                   |   |   |   |   |                                    |                        |                           |                           |             |                                 |                        |                           |                           |             |
| <b>Industrial/Applied Research</b>                       | Up to 50+15 (max 65 %)   | Up to 50+10+15 (max 75 %) | Up to 50+20+15 (max 80 %) | Up to 100 %                             |                   |   |                                   |   |   |   |   |                                    |                        |                           |                           |             |                                 |                        |                           |                           |             |
| <b>Experimental development</b>                          | Up to 25+15 (max 40 %)   | Up to 25+10+15 (max 50 %) | Up to 25+20+15 (max 60 %) | Up to 100 %                             |                   |   |                                   |   |   |   |   |                                    |                        |                           |                           |             |                                 |                        |                           |                           |             |

|  |  |  |
|--|--|--|
| <b>Country</b>   | <b>Slovak Republic</b>   |  |
| <b>Funding organisation</b>  | Slovak Academy of Sciences<br><a href="http://www.sav.sk">http://www.sav.sk</a>  |  |
| <b>National contact persons</b>  | <b>Jan BARANCIK</b> , PhD.<br>Department for International Cooperation of SAS,<br>Slovak Academy of Sciences, Štefánikova 49<br>814 38 - Bratislava, Slovak Republic<br>Tel: +421 2 5751 0137<br>E-mail: <a href="mailto:barancik@up.upsav.sk">barancik@up.upsav.sk</a>  | <b>Martin NOVAK</b> , PhD.<br>Department for International Cooperation of SAS,<br>Slovak Academy of Sciences,<br>Štefánikova 49<br>814 38 - Bratislava, Slovak Republic<br>Tel: +421 2 5751 0179<br>E-mail: <a href="mailto:mnovak@up.upsav.sk">mnovak@up.upsav.sk</a> |
| <b>National programme</b>  | Research in the field of biological, medical and pharmaceutical sciences   |  |
| <b>Funding commitment</b>  | 0.21 Mio € (to be confirmed)   |  |
| <b>Anticipated number of fundable project partners</b>                     | 1-2  |  |
| <b>Maximum funding per grant awarded to a project partner</b>              | up to 105 000 €/per project for 3 year project period  |  |
| <b>Eligibility of projects</b>   | <ul style="list-style-type: none"> <li>■ 3 year transnational projects with 3 or more eligible project consortium partners and from at least 3 different TRANSCAN joint transnational call 2011 funding countries</li> <li>■ Translational projects are encouraged</li> </ul>  |  |
| <b>Eligibility of a partner as a beneficiary institution</b>               | Only research Institutes of the Slovak Academy of Sciences are eligible organisations for funding by SAS (up to 100%). Applicants from other Slovak R&D centres (universities and/or other organisations) have to cover the project costs from their own sources (letter of Commitment). In addition to this, the teams outside of SAS can be consortium members but not the coordinator of the consortium.  |  |
| <b>Eligibility of principal investigator or other research team member</b> | <ul style="list-style-type: none"> <li>■ Each researcher of the core research team of a project consortium Slovak partner (other than the Principal Investigator) must have a job contract with or a fellowship with such a Slovak project partner, lasting until the end of the project or beyond</li> <li>■ The principal Investigator of the research team of a project consortium Slovak partner must be a senior researcher having a job contract with such a project partner, lasting until the end of the granted project or beyond.</li> </ul>                     |  |
| <b>Eligibility of costs, types and their caps</b>                          | <p>Direct costs (DC) : Personnel (max. 15% of DC), Consumables, Equipment (max. 40% of DC) and Travel costs will be as eligible costs.</p> <p>Indirect costs (IC - overheads): max. 20 % of DC. Total eligible costs = DC + IC</p> <p>Training costs shall not be defined as a separate category, but included in other costs items.</p> <p>(<a href="http://www.sav.sk/index.php?lang=sk&amp;charset=&amp;doc=services-news&amp;source_no=25&amp;news_no=5570">www.sav.sk/index.php?lang=sk&amp;charset=&amp;doc=services-news&amp;source_no=25&amp;news_no=5570</a>)</p> |  |

|                         |   |
|-------------------------|---|
| <b>National phase</b>   | Submission of the proposal at a national level will be carried out once the international evaluation and the ranking list have been performed and endorsed by the Call steering committee (CSC) and the Slovak project partner has been informed by the project consortium coordinator and invited by SAS to submit the proposal to it.<br>The Presidium of SAS makes the final decision concerning the approval of funding (according to internal rules of SAS).   |
| <b>Further guidance</b> | <a href="http://www.sav.sk/">http://www.sav.sk/</a> ;<br>133 Act of February 19, 2002 on the Slovak Academy of Sciences,<br>Financial rules for awarding SAS grants for research projects in frame of ERA.Net Programme for research institutes of SAS<br>Principles of allocation of funds for the institutes of SAS to support projects in the field of international scientific cooperation<br>( <a href="http://www.sav.sk/index.php?lang=sk&amp;charset=&amp;doc=services-news&amp;source_no=25&amp;news_no=5570">http://www.sav.sk/index.php?lang=sk&amp;charset=&amp;doc=services-news&amp;source_no=25&amp;news_no=5570</a> ) |

|  |  |
|--|--|
| <b>Country</b>   | <b>SLOVENIA</b>  |
| <b>Funding organisation</b>  | Ministry of Education, Science and Sport (MIZS)  |
| <b>National contact persons</b>  | <b>Dr. Eva Batista</b> Tel.: +3861 478 4754, E-mail: eva.batista@gov.si  |
| <b>National programme</b>  | Projects of international scientific cooperation   |
| <b>Funding commitment</b>  | 0,210 Mio  |
| <b>Anticipated number of fundable project partners</b>                     | Anticipated number of research groups to be funded: 1-2  |
| <b>Maximum funding per grant awarded to a project partner</b>              | For the Slovenian partner within the (one) selected consortium a maximum of 70.000,00 EUR per year (210.000,00 EUR for the total project duration of maximum of 36 months per Slovenian partner) is granted.   |
| <b>Eligibility of projects</b>   | As in the international call text  |
| <b>Eligibility of a partner as a beneficiary institution</b>               | <b>Eligibility of a partner as a beneficiary institution:</b> Research organizations as defined in the national <a href="#">Research and Development Act</a> ( <i>Zakon o raziskovalni in razvojni dejavnosti - ZRRD, Uradni list RS, št. 22/06 – uradno prečiščeno besedilo, 61/06-ZDru-1, 112/07, 9/11 in 57/12-ZPOP-1A</i> ). All participating institutions have to be registered in the Slovenian Research Agency register of research institutions ( <i>Informacijski sistem o raziskovalni dejavnosti v Sloveniji - Sicris</i> ).   |
| <b>Eligibility of principal investigator or other research team member</b> | <b>Eligibility of principal investigator and other research team members:</b> The project activities of the Slovenian partner have to be under the supervision of the <u>primary investigator/primary researcher</u> who fulfills the requirements for project leader as defined in Art. 29 of the national <a href="#">Decree on criteria and standards for allocating resources for the implementation of the research activity, financed from the budget of the Republic of Slovenia</a> ( <i>Uredba o normativih in standardih za določanje sredstev za izvajanje raziskovalne dejavnosti, financirane iz Proračuna Republike Slovenije, Uradni list RS, št. 103/11, 56/12, 15/14 in 103/15</i> , from now on: <i>Decree on criteria and standards</i> ). The criteria are further determined in the <a href="#">Rules on Determining the Fulfillment of Conditions for a Research Project Leader</a> ( <i>Pravilnik o kriterijih za ugotavljanje izpolnjevanja pogojev za vodjo raziskovalnega projekta, Uradni list RS št. 41/09 in 72/11</i> ). All participating researchers have to be <u>registered</u> in the Slovenian Research Agency register of researchers ( <i>Sicris</i> ) and <u>must have available research hours</u> . |
| <b>Eligibility of costs, types and their caps</b>                          | <b>Eligibility of costs:</b> MIZS will fund all eligible costs of Slovenian researchers participating in successful transnational projects, recommended for funding in accordance with the <i>Decree on criteria and standards</i> . Eligible costs are defined based on the FTE value according to the Slovenian Research Agency's research project categorization (A, B, C or D based on the research conducted). Eligible costs must be directly related to the research conducted and should include <u>personnel</u> (according to article 16,18, 22 and 23 of the Decree), <u>material</u> (including travel, consumables and services) and <u>equipment</u> (amortization) costs as elements of the FTE. Indirect costs are eligible. The value is calculated based on the FTE value of category  |

|  |  |
|--|--|
|  | <p>A, B,C, or D research projects, under the condition that costs under each of the specific FTE elements are appropriately decreased (by a max. of 20% for indirect costs).</p> <p><b>Period of eligibility of public expenditures:</b> as of budgetary year 2018 until the end of the budgetary year 2021.</p> <p><b>Period of eligibility of expenditures on the project:</b> from the starting date of the transnational project stipulated in the consortium agreement for a period of maximum of 36 months, with a prescribed additional 30 day period for the payment of invoices related to the project costs. The exact duration of the project will be defined in the contract between MIZS and the selected Slovenian partner, after the consortium agreement between the selected consortium partners enters into force.</p> <p><b>Funding:</b> <u>100 % for research organization</u> (such as universities, public and private research institutes) <u>who's financed activity is non-economic</u> in accordance with the provisions of Community Framework for State Aid for Research and Development and Innovation (OJ EU C 198, 27. 6. 2014). Wide dissemination of research results on a non-exclusive and non-discriminatory basis is required.</p> <p><u>For research organizations, under the provision of Companies Act (Zakon o gospodarskih družbah, Uradni list RS, št. 65/09 - uradno prečiščeno besedilo, 33/11, 91/11, 100/11 - skl. US, 32/12, 57/12, 44/13 - odl. US, 82/13 in 55/15): 80% for small enterprises, 75% for medium sized enterprises and 65% for large enterprises.</u></p> |
| <p><b>For the research project as well as for the capacity building and training activities:</b></p> | <p>Compliant to the Decree.</p>  |
| <p><b>National phase</b><br/><b>Further guidance</b></p>   | <p><b>National contracting negotiations</b> will commence after the projects are selected for funding on the level of the transnational call. National documentation with a statement regarding the agreed starting date of the transnational project signed by the transnational project coordinator will be a prerequisite for signing the contract on national level.</p> <p>The Slovenian National Contact Person is Dr. Eva Batista. Tel.: +3861 478 4754<br/>E-mail: eva.batista@gov.si</p>  |

|   |   |             |         |
|---|---|-------------|---------|
| <b>Country</b>  | <b>Spain</b>  |             |         |
| <b>Funding Organisation</b>                                     | Spanish Association Against Cancer Scientific Foundation (AECC FC)<br><a href="http://www.aecc.es">www.aecc.es</a>  |             |         |
| <b>National Funding Programme</b>                               | Plan estratégico 2016:2020. Ayudas a proyectos: globalización<br><a href="http://www.fundacioncientifica.aecc.es">www.fundacioncientifica.aecc.es</a>   |             |         |
| <b>National Contact Point for the 9th call of NEURON Cofund</b> | Marta Puyol<br>Email: <a href="mailto:marta.puyol@aecc.es">marta.puyol@aecc.es</a><br>Tel: (+34) 913108207  |             |         |
| <b>Initial funding pre-commitment</b>                           | <ul style="list-style-type: none"> <li>• 0.150M€</li> <li>• <u>Only 3 years projects</u></li> <li>• <u>1-2 research groups</u></li> </ul>   |             |         |
| <b>Maximum funding per awarded Spanish project partner</b>      | <ul style="list-style-type: none"> <li>• Up to 200.000 € per partner (only 100.000 € will be awarded by the AECC FC, for additional 100.000 € please see ISCIII funding)</li> <li>• Up to 300.000 € per coordinator (only 150.000 € will be awarded by the AECC FC, for additional 150.000 € please see ISCIII funding)</li> </ul>  |             |         |
| <b>Eligible institutions</b>                                    |   | Coordinator | Partner |
|   | Hospitals, primary health care or public health settings of the Spanish National Health System (SNS) <sup>1</sup>   | YES         | YES     |
|   | Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS) <sup>2</sup>   | YES         | NO      |
|   | CIBER or CIBERNED   | YES         | NO      |
|   | Intramural ISCIII   | YES         | YES     |
|   | Universities  | YES         | YES     |
|   | Research Performance Organizations recognized as such according to the Act 14/2011, of June 1st, of Science, Technology and Innovation, as well as the other ones hold by Public Administrations  | YES         | YES     |
|   | <ol style="list-style-type: none"> <li>1. These institutions may manage research via a foundation regulated in accordance to the Spanish Act 50/2002, of December 26th (a copy of the foundation's statutes may be submitted)</li> <li>2. Accredited according to the RD 339/2004, of February 27th (These institutions may manage research via a foundation regulated according to the Spanish Act 50/ 2002, of December 26th)<br/><a href="http://www.eng.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-institutos-investigacion-sanitaria/listado-de-iis-acreditados.shtml">http://www.eng.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-institutos-investigacion-sanitaria/listado-de-iis-acreditados.shtml</a></li> <li>3. Please note that these entities can only participate if they apply together with Hospitals, primary health care or public health settings of the Spanish National Health System (SNS), Accredited Health</li> </ol> |             |         |



|   | <p>Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS) CIBER or CIBERNED, Intramural ISCIII in the same proposal. It is not allowed to apply independently.</p> <p>NOTE:</p> <p>A. Only one partner per beneficiary institution may be funded within the same proposal</p> <p>B. SMEs and other private companies are encouraged to participate at their own cost, as subcontractors or funded by other sources including CDTI open calls for internationalization</p>  |         |             |         |   |     |     |                 |     |     |                      |     |     |             |  |  |                                   |  |  |           |  |  |
|---|--|---------|-------------|---------|---|-----|-----|-----------------|-----|-----|----------------------|-----|-----|-------------|--|--|-----------------------------------|--|--|-----------|--|--|
| <b>Additional eligibility criteria</b>  | <ul style="list-style-type: none"> <li>Only one proposal per partner is allowed</li> </ul>   |         |             |         |   |     |     |                 |     |     |                      |     |     |             |  |  |                                   |  |  |           |  |  |
| <b>Eligibility of PI and team members</b>   | <ul style="list-style-type: none"> <li>The Principal Investigator (PI) and all members of the research group must belong to the eligible institution or be affiliated to CIBER, CIBERNED or an IIS.</li> </ul> <p>Excluded personnel as Principal Investigator (PI):</p> <ul style="list-style-type: none"> <li>Those undergoing a postgraduate training in Health Specialization (MIR, FIR, QIR, BIR, PIR)</li> <li>Those undergoing research training (e.g. PhD students, or “Río Hortega” contracts)</li> <li>Researchers contracted by a RETIC or a CONSOLIDER</li> <li>Those undergoing postdoctoral training (e.g. “Sara Borrell” or “Juan de la Cierva” contracts)</li> </ul>   |         |             |         |   |     |     |                 |     |     |                      |     |     |             |  |  |                                   |  |  |           |  |  |
| <b>Eligible costs</b>   | <table border="1"> <thead> <tr> <th></th> <th>Coordinator</th> <th>Partner</th> </tr> </thead> <tbody> <tr> <td>Personnel<br/>Up to 3-year, full-time or part-time contracts (only for additional personnel)</td> <td>YES</td> <td>YES</td> </tr> <tr> <td>Small Equipment</td> <td>YES</td> <td>YES</td> </tr> <tr> <td>Travel and Allowance</td> <td>YES</td> <td>YES</td> </tr> <tr> <td>Consumables</td> <td colspan="2">Not eligible (see ISCIII criteria for funding)</td> </tr> <tr> <td>Subcontracting and other services</td> <td colspan="2">Not eligible (see ISCIII criteria for funding)</td> </tr> <tr> <td>Overheads</td> <td colspan="2">Not eligible (see ISCIII criteria for funding)</td> </tr> </tbody> </table> |         | Coordinator | Partner | Personnel<br>Up to 3-year, full-time or part-time contracts (only for additional personnel) | YES | YES | Small Equipment | YES | YES | Travel and Allowance | YES | YES | Consumables | Not eligible (see ISCIII criteria for funding) |  | Subcontracting and other services | Not eligible (see ISCIII criteria for funding) |  | Overheads | Not eligible (see ISCIII criteria for funding) |  |
|   | Coordinator  | Partner |             |         |   |     |     |                 |     |     |                      |     |     |             |  |  |                                   |  |  |           |  |  |
| Personnel<br>Up to 3-year, full-time or part-time contracts (only for additional personnel) | YES  | YES     |             |         |   |     |     |                 |     |     |                      |     |     |             |  |  |                                   |  |  |           |  |  |
| Small Equipment   | YES  | YES     |             |         |   |     |     |                 |     |     |                      |     |     |             |  |  |                                   |  |  |           |  |  |
| Travel and Allowance  | YES  | YES     |             |         |   |     |     |                 |     |     |                      |     |     |             |  |  |                                   |  |  |           |  |  |
| Consumables   | Not eligible (see ISCIII criteria for funding)   |         |             |         |   |     |     |                 |     |     |                      |     |     |             |  |  |                                   |  |  |           |  |  |
| Subcontracting and other services   | Not eligible (see ISCIII criteria for funding)   |         |             |         |   |     |     |                 |     |     |                      |     |     |             |  |  |                                   |  |  |           |  |  |
| Overheads   | Not eligible (see ISCIII criteria for funding)   |         |             |         |   |     |     |                 |     |     |                      |     |     |             |  |  |                                   |  |  |           |  |  |
| <b>Special Consideration</b>  | The AECC Scientific Foundation will co-fund the awarded research projects with the ISCIII on a cost-basis manner.  |         |             |         |   |     |     |                 |     |     |                      |     |     |             |  |  |                                   |  |  |           |  |  |
| <b>Mandatory acknowledgement</b>  | Any publication resulting from the granted projects must acknowledge “Award no. XX by AECC Scientific Foundation and within the TRANSCAN framework” even after the end of the project  |         |             |         |   |     |     |                 |     |     |                      |     |     |             |  |  |                                   |  |  |           |  |  |

|  |   |             |         |
|--|---|-------------|---------|
| <b>Country</b>   | <b>SPAIN</b>  |             |         |
| <b>Funding organisation</b>  | National Institute of Health Carlos III   |             |         |
| <b>National contact persons</b>  | <b>Dr. Elsa Moreda</b> tel: +34 91 822 28 74; email: emoreda@isciii.es  |             |         |
| <b>National programme</b>  | Acción Estratégica en salud (AES 2017)<br><a href="http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-financiacion/convocatorias-ayudas-accion-estrategica-salud.shtml">http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-financiacion/convocatorias-ayudas-accion-estrategica-salud.shtml</a> |             |         |
| <b>Funding commitment</b>  | € 0,15 Mio  |             |         |
| <b>Anticipated number of fundable project partners</b>   | 1   |             |         |
| <b>Maximum funding per grant awarded to a project partner</b>  | Up to 100.000 € per partner<br>Up to 150.000 € per coordinator  |             |         |
| <b>Eligibility of projects</b>   | Only 3-year projects  |             |         |
| <b>Eligibility of a partner as a beneficiary institution</b>   |   | Coordinator | Partner |
|  | Hospitals, primary health care or public health settings of the Spanish National Health System (SNS) <sup>1</sup>   | YES         | YES     |
|  | Public Cancer Research Centres (those working exclusively in the field of Cancer diseases)  | YES         | YES     |
|  | Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS) <sup>2</sup>   | YES         | NO      |
|  | CIBER or CIBERNED   | YES         | NO      |
|  | <b>In addition to the Spanish entities listed above we allow the following entities participation<sup>3</sup></b>   |             |         |
|  | Universities <sup>3</sup>   | YES         | YES     |
|  | Research Performance Organizations recognized as such according to the Act 14/2011, of June 1st, of Science, Technology and Innovation, as well as the other ones hold by Public Administrations <sup>3</sup>   | YES         | YES     |
| <sup>1</sup> These institutions may manage research via a foundation regulated in accordance to the Spanish Act 50/2002, of December 26th<br>(a copy of the foundation's statutes may be submitted).<br><sup>2</sup> Accredited according to the RD 339/2004, of February 27th (These institutions may manage research via a foundation regulated according to the Spanish Act 50/ 2002, of December 26th) |   |             |         |

|  | <p><a href="http://www.eng.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-institutos-investigacion-sanitaria/listado-de-iis-acreditados.shtml">http://www.eng.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-institutos-investigacion-sanitaria/listado-de-iis-acreditados.shtml</a>.</p> <p><sup>3</sup> Please note that these entities can only participate if they apply together with Hospitals, primary health care or public health settings of the Spanish National Health System (SNS), Accredited Health Research Institutes (Institutos de Investigación Sanitaria Acreditados, IIS), CIBER or CIBERNED in the same proposal. It is not allowed to apply independently.</p> <p><b>NOTE:</b></p> <ul style="list-style-type: none"> <li>- Only one partner per beneficiary institution may be funded within the same proposal.</li> <li>- SMEs and other private companies are encouraged to participate at their own cost, as subcontractors or funded by other sources including CDTI's open calls for internationalization</li> </ul>   |                       |             |         |   |  |                     |                               |                       |                       |                                    |                      |                      |  |             |         |  |                     |                       |                       |                      |                      |  |         |                     |                       |                      |
|--|--|-----------------------|-------------|---------|---|--|---------------------|-------------------------------|-----------------------|-----------------------|------------------------------------|----------------------|----------------------|--|-------------|---------|--|---------------------|-----------------------|-----------------------|----------------------|----------------------|--|---------|---------------------|-----------------------|----------------------|
| <p><b>Eligibility of principal investigator or other research team member</b></p>  | <p>The Principal Investigator (PI) and all members of the research group must belong to the eligible institution or be affiliated to CIBER, CIBERNED or an IIS.</p> <p>Excluded personnel as Principal Investigator (PI):</p> <ul style="list-style-type: none"> <li>- Those undergoing a postgraduate training in Health Specialization (MIR, FIR, QIR, BIR, PIR)</li> <li>- Those undergoing research training (e.g. PhD students, or "Río Hortega" contracts)</li> <li>- Researchers contracted by a RETIC or a CONSOLIDER</li> <li>- Those undergoing postdoctoral training (e.g. "Sara Borrell" or "Juan de la Cierva" contracts)</li> </ul> <p><b>NOTE:</b></p> <ul style="list-style-type: none"> <li>- Only one proposal per partner is allowed.</li> <li>- Researchers with ongoing TRANSCAN projects in 2018 cannot apply to the current call except if the applicant is the coordinator.</li> <li>- There is no other incompatibility with AES 2017. Incompatibilities with other calls are subject to their respective specifications</li> </ul>   |                       |             |         |   |  |                     |                               |                       |                       |                                    |                      |                      |  |             |         |  |                     |                       |                       |                      |                      |  |         |                     |                       |                      |
| <p><b>Eligibility of costs, types and their caps</b></p>   | <table border="1"> <thead> <tr> <th data-bbox="770 1034 1256 1070"></th> <th data-bbox="1256 1034 1800 1070">Coordinator</th> <th data-bbox="1800 1034 2033 1070">Partner</th> </tr> </thead> <tbody> <tr> <td data-bbox="770 1070 1256 1294"> <p><b>Personnel</b><br/>Up to 3-year, full-time or part-time contracts (only for additional personnel)<br/>Excluded: Students and fellowships</p> </td> <td data-bbox="1256 1070 1800 1294"> <p>Total cost per annual full-time contract:</p> <ul style="list-style-type: none"> <li>• Technical expert, higher degree: 29.500 €</li> <li>• Technical expert, medium degree: 24.500 €</li> <li>• Technical expert, FP II: 20.500 €</li> </ul> </td> <td data-bbox="1800 1070 2033 1294"> <p>Not eligible</p> </td> </tr> <tr> <td data-bbox="770 1294 1256 1331"> <p><b>Small Equipment</b></p> </td> <td data-bbox="1256 1294 1800 1331"> <p>Up to 40.000 €</p> </td> <td data-bbox="1800 1294 2033 1331"> <p>Up to 20.000 €</p> </td> </tr> <tr> <td data-bbox="770 1331 1256 1369"> <p><b>Travel and Allowance</b></p> </td> <td data-bbox="1256 1331 1800 1369"> <p>Up to 9.000 €</p> </td> <td data-bbox="1800 1331 2033 1369"> <p>Up to 4.500 €</p> </td> </tr> </tbody> </table> |                       | Coordinator | Partner | <p><b>Personnel</b><br/>Up to 3-year, full-time or part-time contracts (only for additional personnel)<br/>Excluded: Students and fellowships</p> | <p>Total cost per annual full-time contract:</p> <ul style="list-style-type: none"> <li>• Technical expert, higher degree: 29.500 €</li> <li>• Technical expert, medium degree: 24.500 €</li> <li>• Technical expert, FP II: 20.500 €</li> </ul> | <p>Not eligible</p> | <p><b>Small Equipment</b></p> | <p>Up to 40.000 €</p> | <p>Up to 20.000 €</p> | <p><b>Travel and Allowance</b></p> | <p>Up to 9.000 €</p> | <p>Up to 4.500 €</p> | <table border="1"> <thead> <tr> <th data-bbox="1256 1034 1800 1070">Coordinator</th> <th data-bbox="1800 1034 2033 1070">Partner</th> </tr> </thead> <tbody> <tr> <td data-bbox="1256 1070 1800 1294"> <p>Total cost per annual full-time contract:</p> <ul style="list-style-type: none"> <li>• Technical expert, higher degree: 29.500 €</li> <li>• Technical expert, medium degree: 24.500 €</li> <li>• Technical expert, FP II: 20.500 €</li> </ul> </td> <td data-bbox="1800 1070 2033 1294"> <p>Not eligible</p> </td> </tr> <tr> <td data-bbox="1256 1294 1800 1331"> <p>Up to 40.000 €</p> </td> <td data-bbox="1800 1294 2033 1331"> <p>Up to 20.000 €</p> </td> </tr> <tr> <td data-bbox="1256 1331 1800 1369"> <p>Up to 9.000 €</p> </td> <td data-bbox="1800 1331 2033 1369"> <p>Up to 4.500 €</p> </td> </tr> </tbody> </table> | Coordinator | Partner | <p>Total cost per annual full-time contract:</p> <ul style="list-style-type: none"> <li>• Technical expert, higher degree: 29.500 €</li> <li>• Technical expert, medium degree: 24.500 €</li> <li>• Technical expert, FP II: 20.500 €</li> </ul> | <p>Not eligible</p> | <p>Up to 40.000 €</p> | <p>Up to 20.000 €</p> | <p>Up to 9.000 €</p> | <p>Up to 4.500 €</p> | <table border="1"> <thead> <tr> <th data-bbox="1800 1034 2033 1070">Partner</th> </tr> </thead> <tbody> <tr> <td data-bbox="1800 1070 2033 1294"> <p>Not eligible</p> </td> </tr> <tr> <td data-bbox="1800 1294 2033 1331"> <p>Up to 20.000 €</p> </td> </tr> <tr> <td data-bbox="1800 1331 2033 1369"> <p>Up to 4.500 €</p> </td> </tr> </tbody> </table> | Partner | <p>Not eligible</p> | <p>Up to 20.000 €</p> | <p>Up to 4.500 €</p> |
|  | Coordinator  | Partner               |             |         |   |  |                     |                               |                       |                       |                                    |                      |                      |  |             |         |  |                     |                       |                       |                      |                      |  |         |                     |                       |                      |
| <p><b>Personnel</b><br/>Up to 3-year, full-time or part-time contracts (only for additional personnel)<br/>Excluded: Students and fellowships</p>  | <p>Total cost per annual full-time contract:</p> <ul style="list-style-type: none"> <li>• Technical expert, higher degree: 29.500 €</li> <li>• Technical expert, medium degree: 24.500 €</li> <li>• Technical expert, FP II: 20.500 €</li> </ul>   | <p>Not eligible</p>   |             |         |   |  |                     |                               |                       |                       |                                    |                      |                      |  |             |         |  |                     |                       |                       |                      |                      |  |         |                     |                       |                      |
| <p><b>Small Equipment</b></p>  | <p>Up to 40.000 €</p>  | <p>Up to 20.000 €</p> |             |         |   |  |                     |                               |                       |                       |                                    |                      |                      |  |             |         |  |                     |                       |                       |                      |                      |  |         |                     |                       |                      |
| <p><b>Travel and Allowance</b></p>   | <p>Up to 9.000 €</p>   | <p>Up to 4.500 €</p>  |             |         |   |  |                     |                               |                       |                       |                                    |                      |                      |  |             |         |  |                     |                       |                       |                      |                      |  |         |                     |                       |                      |
| Coordinator  | Partner  |                       |             |         |   |  |                     |                               |                       |                       |                                    |                      |                      |  |             |         |  |                     |                       |                       |                      |                      |  |         |                     |                       |                      |
| <p>Total cost per annual full-time contract:</p> <ul style="list-style-type: none"> <li>• Technical expert, higher degree: 29.500 €</li> <li>• Technical expert, medium degree: 24.500 €</li> <li>• Technical expert, FP II: 20.500 €</li> </ul> | <p>Not eligible</p>  |                       |             |         |   |  |                     |                               |                       |                       |                                    |                      |                      |  |             |         |  |                     |                       |                       |                      |                      |  |         |                     |                       |                      |
| <p>Up to 40.000 €</p>  | <p>Up to 20.000 €</p>  |                       |             |         |   |  |                     |                               |                       |                       |                                    |                      |                      |  |             |         |  |                     |                       |                       |                      |                      |  |         |                     |                       |                      |
| <p>Up to 9.000 €</p>   | <p>Up to 4.500 €</p>   |                       |             |         |   |  |                     |                               |                       |                       |                                    |                      |                      |  |             |         |  |                     |                       |                       |                      |                      |  |         |                     |                       |                      |
| Partner  |  |                       |             |         |   |  |                     |                               |                       |                       |                                    |                      |                      |  |             |         |  |                     |                       |                       |                      |                      |  |         |                     |                       |                      |
| <p>Not eligible</p>  |  |                       |             |         |   |  |                     |                               |                       |                       |                                    |                      |                      |  |             |         |  |                     |                       |                       |                      |                      |  |         |                     |                       |                      |
| <p>Up to 20.000 €</p>  |  |                       |             |         |   |  |                     |                               |                       |                       |                                    |                      |                      |  |             |         |  |                     |                       |                       |                      |                      |  |         |                     |                       |                      |
| <p>Up to 4.500 €</p>   |  |                       |             |         |   |  |                     |                               |                       |                       |                                    |                      |                      |  |             |         |  |                     |                       |                       |                      |                      |  |         |                     |                       |                      |

|  |  |  |
|--|--|--|
|  | <b>Consumables</b>   | Up to 100% of direct cost  |
|  | <b>Subcontracting and other services</b>   | Up to 50% of direct cost<br>Private (bio)companies and SMEs included                     |
|  | <b>Overheads</b>   | Up to 21% of direct cost, included in the maximum funding per grant awarded to a partner |
| <b>National phase<br/>Further guidance</b> | National applications will be required from applicants officially invited by ISCIII<br>Any publication resulting from the granted projects must acknowledge " <i>Award no. XX by ISCIII through AES 2017 and within the TRANSCAN framework</i> " even after the end of the project |  |

|  |  |
|--|--|
| <b>Country/Region</b>  | <b>Spain / Asturias</b>  |
| <b>Funding organisation</b>  | The Foundation for the support of the Applied Scientific Research and Technology in Asturias (FICYT)<br><a href="http://www.ficyt.es">http://www.ficyt.es</a>  |
| <b>Regional contact persons</b>  | <b>Ms. Inés REY HIDALGO</b><br>Tel: +34 985 20 74 34<br>E-mail: <a href="mailto:inesrey@ficyt.es">inesrey@ficyt.es</a>   |
| <b>Regional programme</b>  | Regional Programme for funding Science, Technology and Innovation  |
| <b>Funding commitment</b>  | € 0.2 Mio.   |
| <b>Anticipated number of fundable project partners</b>                     | 2 TRANSCAN-2 transnational project partners  |
| <b>Maximum funding per grant awarded to a project partner</b>              | <p>Only one grant per fundable project partner:</p> <ul style="list-style-type: none"> <li>Up to 150,000 € (overheads included) per project coordinator (up to 200.000 € per project for the whole Asturian part funded by the Regional Ministry in case more than one Asturian partner participates in the same proposal and an Asturian eligible institution coordinates the project consortium);</li> <li>Up to 100,000 € (overheads included) per project partner (up to 150.000 € per project for the whole Asturian part funded by the Regional Ministry in case more than one Asturian partner participates in the same proposal, and both takes part as partners in the consortium).</li> </ul> <p><i>Funding by FICYT is subject to the approval of the relevant annual appropriations by the Regional Parliament in Asturias</i></p> |
| <b>Eligibility of projects</b>   | <ul style="list-style-type: none"> <li>Applicants must fulfill the eligibility requirements of the TRANSCAN-2 international call.</li> <li>Minimum duration of the project: 12 months for industrial research / 9 months for experimental development.</li> <li>Maximum duration of the project: 36 months.</li> <li>Industry must demonstrate incentive effect of the aid.</li> </ul>   |
| <b>Eligibility of a partner as a beneficiary institution</b>               | Applications must be submitted by entities located in Asturias or, in case of companies, with a production center in Asturias.   |
| <b>Eligibility of principal investigator or other research team member</b> | There will be a contact person taking part in the project to act as intermediary with the funding agency.  |
| <b>Eligibility of costs, types and their caps</b>                          | <ul style="list-style-type: none"> <li>Expenses can only be committed and invoices charged with dates of each year in which the Asturian aid is granted</li> </ul>   |

|                         |   |
|-------------------------|---|
|                         | <ul style="list-style-type: none"> <li>• Own staff: only for companies / only that employees dedicated to the research project submitted to TRANSCAN-2 international call</li> <li>• New staff: according to the regulation of the regional call.</li> <li>• Equipments: depreciation costs.</li> <li>• Consumables.</li> <li>• Subcontracts: up to 50% of the direct costs of the regional project.</li> <li>• Other costs: travels, accommodation costs and allowances (only for staff appearing in the Personnel area of the proposal that directly takes part in the project); patenting costs; audit costs.</li> <li>• Overheads: according to the regulation of the regional call.</li> </ul> |
| <b>Regional phase</b>   | The submission of the proposal at regional level will be carried out once the international evaluation and the ranking list have been performed and endorsed by the Call Steering Committee (CSC) and the Spanish project partner IP has been informed by the project consortium coordinator.   |
| <b>Further guidance</b> | All applicants must comply with all the Regulations applicable to public funding at European, National and Regional level, and with all those Regulations indicated in the Regional Regulatory Bases and calls<br>Link to the Regulatory Bases: <a href="http://www.ficyt.es/pri/docs/BasesREguladorasTranscan.pdf">http://www.ficyt.es/pri/docs/BasesREguladorasTranscan.pdf</a>   |

|  |   |
|--|---|
| <b>Country</b>   | <b>Taiwan</b>   |
| <b>Funding organisation</b>  | Ministry of Science and Technology<br><a href="http://www.most.gov.tw/">http://www.most.gov.tw/</a>   |
| <b>National contact persons</b>  | <b>Dr. Louis CHEN</b><br>Ministry of Science and Technology (Taiwan)<br>Tel:+886-2-2737-7959<br>E-mail: <a href="mailto:ymchen@most.gov.tw">ymchen@most.gov.tw</a>  |
| <b>National programme</b>  | Medical Research Administration   |
| <b>Funding commitment</b>  | 0.5 Mio. €  |
| <b>Anticipated number of fundable project partners</b>                     | 2-3   |
| <b>Maximum funding per grant awarded to a project partner</b>              | NTD 3Mio/Year (roughly €70,000/Year)  |
| <b>Eligibility of projects</b>   | The standard funding policy and eligibility rules set by the Ministry of Science and Technology applied.  |
| <b>Eligibility of a partner as a beneficiary institution</b>               | All research institutes, universities, hospitals, public organisations in Taiwan endorsed by the Ministry of Science and Technology as beneficiary institution.   |
| <b>Eligibility of principal investigator or other research team member</b> | The standard funding policy and eligibility rules set by the Ministry of Science and Technology applied.  |
| <b>Eligibility of costs, types and their caps</b>                          | Personnel, Consumables, Hosting expenses for foreign researchers, Travel expenses for international destinations-joint research & overseas studies  |
| <b>National phase</b>  | No official national application is needed in the pre-proposal or full proposal phase. But must notify the national contact person in the Ministry of Science and Technology of your submission to the TRANSCAN-2 joint transnational call via email, together with your application as an attachment.<br>A formal proposal must be submitted electronically via the Ministry's web submission portal together with an official missive sent from your institution, submission should be done after the joint TRANSCAN JTC 2014 peer review has been completed and the final (scientific) ranking list has been performed and endorsed by the Call Steering Committee. The submitted proposal will formally be granted by the Ministry of Science and Technology after an administrative and scientific processing. |
| <b>Further guidance</b>  | Refer to the official announcement by the Ministry of Science and Technology for more information<br>( <a href="http://www.most.gov.tw/">http://www.most.gov.tw/</a> )  |

|  |   |  |  |
|--|---|--|--|
| <b>Country</b>   | <b>TURKEY</b>   |  |  |
| <b>Funding organisation</b>  | The Scientific and Technological Research Council of Turkey (TÜBİTAK)   |  |  |
| <b>National contact persons</b>  | A.Özge Gözay +90312 2989425 ncphealth@tubitak.gov.tr  |  |  |
| <b>National programme</b>  | 1001- The Support Program for Scientific and Technological Research Projects  |  |  |
| <b>Funding commitment</b>  | € 0,35 Mio  |  |  |
| <b>Anticipated number of fundable project partners</b>                     | 2-3   |  |  |
| <b>Maximum funding per grant awarded to a project partner</b>              | Up to 110.000 € per partner excluding overhead  |  |  |
| <b>Eligibility of projects</b>   | Maximum 36 months   |  |  |
| <b>Eligibility of a partner as a beneficiary institution</b>               | The funding is granted to Principal Investigators from universities, public or private sector. The PI is subject to eligibility check.  |  |  |
| <b>Eligibility of principal investigator or other research team member</b> | <p><b>Project Manager, Researchers and Advisors:</b></p> <ul style="list-style-type: none"> <li>- University personnel should have a PhD degree.</li> <li>- Those working in a public institution or a private corporation should have an undergraduate degree.</li> <li>- Except advisors, the project manager and researchers should reside and work in Turkey.</li> <li>- A researcher should have a contribution of at least 10% of the project workload.</li> <li>- An advisor is allowed if the project requires special expertise on a specific subject. The number of advisors in a project is limited to the number of specific subjects in the project. The role of advisor in the project should be explained in detail in the project proposal.</li> </ul> <p><b>NOTE:</b><br/>University rectors and vice rectors, deans, head of academy/institute, surgeons general, general secretaries, general managers, state department heads and members of the executive committee/advisory board of TÜBİTAK groups cannot be the project manager in any project if they are working in those positions as of the application date. However, they can be researchers in at most two projects.</p> |  |  |
| <b>Eligibility of costs, types and their caps</b>                          |   | <b>Coordinator</b>   | <b>Partner</b>   |
|  | <p><b>Personnel</b><br/>Up to 3-year, full-time or part-time contracts (only for additional personnel)<br/>Excluded: PI</p>   | <p>The costs can not be declared in the project budget, but provided by TUBITAK as an extra grant. (Proje Teşvik İkramesi)</p> <ul style="list-style-type: none"> <li>•</li> </ul> | <p>PI is excluded.<br/>Other researchers are eligible for funding.</p> |
|  | <b>Small Equipment</b>  | Must be used for the project   |  |



|   |   |                                    |
|---|---|------------------------------------|
|   | <b>Travel and Allowance</b>   | Up to 25.000 TL, app 7000 €        |
|   | <b>Consumables</b>  | Up to 100% of direct cost          |
|   | <b>Subcontracting and other services</b>  |                                    |
|   | <b>Overheads</b>  | Not eligible, provided as an extra |
| <b>For the research project as well as for the capacity building and training activities:</b> | Capacity building activities are not eligible for funding from TUBITAK.   |                                    |
| <b>National phase<br/>Further guidance</b>  | Participants from Turkey should also submit their proposals in Turkish to TUBITAK electronically via <a href="http://uidb-pbs.tubitak.gov.tr">uidb-pbs.tubitak.gov.tr</a> by 6 <sup>th</sup> of February for pre-proposals and no later than 1 <sup>st</sup> of June for the full proposal stage. The signed hard copy should be sent via regular mail within one month after both deadlines. |                                    |